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Glioblastomas are the most common form of malignant primary brain tumor and an important 
cause of morbidity and mortality. In recent years there have been important advances in 
understanding the molecular pathogenesis and biology of these tumors, but this has not 
translated into significantly improved outcomes for patients. In this consensus review from 
the Society For Neuro-Oncology (SNO) and the European Association of Neuro-Oncology 
(EANO), the current management of isocitrate dehydrogenase-wildtype (IDHwt) 
glioblastomas will be discussed. In addition, novel therapies such as targeted molecular 
therapies, agents targeting DNA damage response and metabolism, immunotherapies and 






































































































































Glioblastomas are the most common type of malignant primary brain tumor, and account for 
the majority of deaths among patients with primary brain tumors.
1
 Although there has been 
progress in understanding the biology of these tumors, this has not translated into significant 
improvements in therapies or outcomes for patients. In this consensus review from the 
Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology 
(EANO) recent advances in the management of glioblastoma are discussed, as well as the 
current challenges and future directions for research. The focus will be on the 90-95% of 
glioblastomas that do not harbor isocitrate dehydrogenase (IDH) mutations (IDHwt) and have 
a worse prognosis.
2,3
 We concur with the current considerations to regroup IDH-mutant 
glioblastomas with other IDH-mutant gliomas in the framework of the revision of the World 
Health Organization (WHO) classification of brain tumors, and to restrict the term 
“glioblastoma” to tumors without IDH mutations.4 
 
Epidemiology  
The overall age-adjusted incidence of glioblastoma in the United States is 3.22/100,000 
persons, and increases with advanced age at diagnosis and male sex (Figure 1A, Central 
Brain Tumor Registry of the United States (CBTRUS) 2012-2016).
1
 Incidence also varies 
worldwide.
5
 Recent data shows no trend towards increased incidence in the US or Canada,
6
 
although data from England indicate that the incidence is increasing.
7,8
 These differences 
might reflect differing surveillance procedures, coding, and changes in classifications of 
glioblastoma over time.
2
 Glioblastomas contribute disproportionately to morbidity and 
mortality, with a 5-year overall relative survival of only 6.8%, which varies by age at 




































































































































Known risk factors for glioblastoma account for only a small proportion of cases.
9
 In multiple 
independent studies, one risk factor, ionizing radiation exposure to the head and neck, and 
one protective factor, history of atopic diseases (including allergies, asthma, eczema, and hay 
fever), have been validated for all brain tumors (as reviewed in 
9
). While cell phone use, i.e. 
non-ionizing radiation exposure, has been heavily studied as a potential risk factor for brain 
tumors, studies have shown no consistent evidence of any association (as reviewed in 
9,10
). 
However, the latency period for disease after exposure to non-ionizing radiation is not 
known, hence continued careful monitoring of the incidence trend is advised.  
The vast majority of glioblastoma patients do not have a family history of cancer. 
Approximately 5% of all gliomas are familial
11
 and there are multiple rare Mendelian 
inherited syndromes that involve adult glioma and glioblastoma
12
 (Table 1 adapted from
9
). 
The frequency of germline variants is higher than expected based on family history data with 
up to 13% of glioma patients harboring at least one deleterious or likely deleterious alteration 
in the germline.
13
 Genome-wide association studies (GWAS) of genetic risk factors have 
validated 25 single nucleotide polymorphisms associated with increased risk for glioma, 
where 11 are specific to glioblastoma.
14
 While the biological significance of these 
associations remains to be elucidated, this genome-wide approach identified loci containing 
critical glioma genes such as TERT, RTEL1, EGFR, and CDKN2B.
14
 The majority of these 
loci are associated with molecularly defined glioma subtypes.
15
 Continued improvements in 
accurate measurement of potential risk factors and advances in technology allowing for 
discovery of additional germline and tumor molecular features will be critical to future 





































































































































Glioblastomas are thought to arise from neuroglial stem or progenitor cells and are 
characterized by molecular heterogeneity. Detailed discussion of glioblastoma biology is 




Molecular Pathogenesis and Genomics 
Molecular profiling has identified genes and core pathways that are commonly mutated in 




 Extension of this work to more tumors and additional 
dimensions (gene expression, DNA methylation) identified three main glioblastoma 
subgroups, each enriched for specific somatic alterations. The Proneural gene 
expression/Receptor Tyrosine Kinase (RTK) I/LGm6 DNA methylation group is marked by 
cyclin-dependent kinase 4 (CDK4) and platelet derived growth factor alpha (PDGFR 
amplifications and is most common in relatively younger adults. The Classical gene 
expression/Classic-like/RTK II DNA methylation group shows a high frequency of epidermal 
growth factor receptor (EGFR) amplifications and homozygous loss of cyclin-dependent 
kinase inhibitor 2A/B (CDKN2A/B). The Mesenchymal/Mesenchymal-like subtype is 
enriched for tumors with Neurofibromatosis Type 1 (NF1) loss and increased tumor 
infiltration with macrophages. These three groups, and mixed entities between them, account 
for the vast majority of glioblastomas, and are all associated with telomerase reverse 
transcriptase (TERT) promoter mutations.
27,28,29,30
 The molecular classification of 
glioblastoma into distinct subtypes provides a framework for research, but its clinical utility 
remains unclear. None of the glioblastoma subtypes are predictive for treatment response to 
current therapies, and assignment of glioblastoma subtype can be challenging in some tumors 
due to apparent coexistence of multiple subtypes within the same tumor, and subtype 



































































































































One important finding in more recent studies has been the identification of rare 
glioblastoma entities and their properties. For example, the alternative lengthening of 
telomeres (ALT) phenotype, defined by ATRX mutation associated with TP53 mutation, is 
mostly found in glioblastomas with mutations in IDH1/2, H3K27M, or H3G34R. FGFR3-
TACC3 fusion positive glioblastomas have been found to activate oxidative phosphorylation 
and appear to be metabolically distinct from the more common glycolytic glioblastomas.
31
 
Epigenetic tumor profiles have been particularly informative in distinguishing tumor entities 
beyond glioma, as they comprise information retained from the cell of origin and acquired 
tumor associated changes. Characteristic epigenetic patterns are associated with certain 
presumed driver mutations, including mutant IDH1/2, mutations in either H3F3A or 
HIST1H3B genes, specifically H3K27M in diffuse midline gliomas, and H3G34R/H3G34V 




After first-line therapy, which typically includes surgical resection, radiation and 
chemotherapy, tumor cell subclones may emerge with distinct features, for example 
deficiency in DNA mismatch repair (MMR).
34,35
 About 10% of recurrent, post-temozolomide 
(TMZ) glioblastomas show a markedly higher mutation rate.
36
 DNA “hypermutation” is 
associated with germline defects in MMR genes and can be acquired following therapy with 
DNA alkylating agents,
37,38,39
 the latter occurring more commonly in MGMT-methylated 
gliomas, including those with IDH mutations. Oncogene amplification on extrachromosomal 
DNA, which is common in sporadic adult glioblastoma, likely represents another mechanism 
for tumor cells to overcome scarcity in resources within the tumor microenvironment.
40,41
 
Comparison of tumor samples obtained at diagnosis and at recurrence show that 80% of 




































































































































 Mutations of PIK3CA, TERT and EGFR amplification in the primary tumor were 
usually retained in the recurrent tumor, whereas amplifications of PDGFRA, mutations in 
EGFR and presence of the EGFRvIII rearrangement were the genetic events most likely to be 
lost. The most frequent genetic changes acquired in recurrent tumors included TP53, EGFR, 
and PTEN mutations. These molecular changes between initial and recurrent tumors may 
potentially affect the design of clinical trials for recurrent glioblastomas if the tumor 
genotype is based on analysis of the initial tumor. For trials targeting genetic changes that are 
frequently altered at recurrence, rebiopsy may be indicated. 
 
Novel sequencing technologies add another layer of detail to our understanding of 
intratumoral heterogeneity and tumor evolution in glioblastoma. Single-cell transcriptomics 
show that glioblastomas are mixtures of cells from each of the three gene expression 
subtypes, not one single category,
43
 corroborating previous findings from multi-sector bulk 
gene expression profiling.
44
 Single-cell DNA profiling confirmed prior fluorescence in situ 
hybridization (FISH) findings, showing that many glioblastomas contain admixtures of 
subclones,
45
 each of which has amplification of a different receptor tyrosine kinase (e.g., 
EGFR, PDGFRA, and MET).
46,47
 More recently, single-cell analyses of glioblastoma samples 
revealed four cellular states within individual tumor samples that demonstrate plasticity and 
are influenced by tumor genetics and the microenvironment.
19
 Lastly, sequencing of 
circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) can yield a genetically faithful 
snapshot of the glioma genome in 50% of patients and may eventually obviate the need for 
tumor re-biopsy in certain instances.
48
 As technology improves, evaluation of plasma ctDNA 



































































































































Genomic profiling has advanced our understanding of the molecular pathogenesis of 
glioblastoma and identified opportunities for the development of genotype-directed therapies 
for subsets of patients. Thus far, however, treatment outcomes for patients with glioblastoma 
have not improved despite this knowledge. Silencing of O
6
-methylguanine-DNA 
methyltransferase (MGMT) mediated DNA repair, typically the result of MGMT promoter 
methylation and loss of the second allele of chromosome 10, currently remains the only 
predictive biomarker of treatment response to temozolomide.
49
  It is thus critical to annotate 
the molecular data with relevant clinical information through cooperative data sharing efforts 
such as the Glioma Longitudinal Analysis (GLASS) Consortium,
42
 and to incorporate 
prospective tumor profiling into hypothesis-driven, genotype-directed clinical trials. 
 
Pathology and Classification of Glioblastoma 
The pathologic hallmarks of glioblastoma are that of a diffusely infiltrative neoplasm with 
astroglial appearance (i.e. angulated nuclei and irregular chromatin), microvascular 
proliferation and/or pseudopalisading necrosis.
50
 (Figure 3) Mitoses are usually easy to 
identify. Some variants include giant cell astrocytoma (which tends to have a high frequency 
of TP53 mutations but only rare EGFR amplifications) and gliosarcoma. Epithelioid 
glioblastoma resembles metastatic poorly-differentiated carcinoma, and is characterized by 
frequent BRAFV600E mutations,
2
 although many of these tumors may be difficult to 
distinguish from pleomorphic xanthoastrocytomas.
51
 (Figure 3) 
Occasionally, a tumor specimen does not show the classic histopathologic features of a 
glioblastoma. Before the era of integrated histopathology-molecular classification, such 
tumors would have been assigned a lower WHO grade. However, numerous studies have 
consistently shown that if such a tumor contains the molecular signature of a glioblastoma, it 


































































































































cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS 
Tumor Taxonomy), which recommended diagnostic criteria for “diffuse astrocytic gliomas, 
IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.”52 In the absence of 
IDH mutations, either TERT promoter mutations, the combination of gain of chromosome 7 
and loss of chromosome 10, or EGFR amplification are now considered sufficient molecular 
evidence of glioblastoma with similar clinical outcome, even when histologic examination 
only meets WHO grade II or III criteria.
52,53
 The recently described CNS tumor methylation 
classifier
33
 represents a major advance in the diagnostic armamentarium in the goal of 
diagnostic accuracy of brain tumors, and specific glioblastoma subclasses are defined.  While 
the clinical utility of these glioblastoma subtypes is not yet shown, use of the classifier to 
confirm a glioblastoma diagnosis can be helpful in selected cases, especially in unusual 
clinical situations (for example, unusual histopathology or history of long-term patient 
survival). 
Conversely, mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) in adult diffuse 
gliomas allow prediction of extended patient survival.
3,54
 A fast, inexpensive upfront screen 
for IDH mutation is mutation-sp cific immunohistochemistry for the most common variant, 
IDH1 R132H, which comprises well over 90% of all IDH mutations in glioblastoma.
54,55
 
Reflex sequencing for non-canonical IDH mutations, such as IDH2 (codon 172), and non-
R132H mutations in IDH1 (for example R132C or R132S), is common practice at many 
institutions, especially when it is part of a larger next-generation sequencing (NGS) panel. 
However, targeted sequencing for “antibody-negative” glioblastoma (i.e. tumors which are 
not positive on IDH1 R132H immunohistochemistry) is considered optional when patients 
are ≥55 years old, since IDH mutations overall, and especially those that are non-canonical, 
are very uncommon in older patients.
56
 On a practical level, it is also very unusual for a 


































































































































and/or unequivocal pseudopalisading necrosis.
57
 Finally, the use of ATRX 
immunohistochemistry can be a useful screen, since most cases of IDH-mutant glioblastoma 
show concomitant loss of ATRX (although not all cases of histologically-defined glioblastoma 
with ATRX loss are IDH-mutant).  In keeping with the distinct biology and clinical behavior 
of Grade IV gliomas as a function of IDH mutation status, the cIMPACT-NOW consensus 
group suggests that the term “glioblastoma” no longer applies to IDH-mutant tumors, and 
suggests instead the term “Astrocytoma, IDH-mutant, WHO Grade IV” for such tumors, to 





Genomic profiling has advanced our understanding of the molecular pathogenesis of 
glioblastoma and identified opportunities for the development of genotype-directed therapies 
for subsets of patients. Thus far, however, treatment outcomes for glioblastoma patients have 
not improved despite this knowledge.  
Multiple phase III trials have shown that the presence of MGMT promoter 
methylation results in ap roximately 50% longer median survival for glioblastoma patients 
treated with TMZ.
49,58,59
 In glioblastomas that lack MGMT promoter methylation TMZ has 
little or no benefit.
49,60
 Whether TMZ may be withheld from these patients, especially in the 




There are multiple ways to test for MGMT promoter methylation, including 
methylation-specific polymerase chain reaction (PCR), methylation-specific high-resolution 




































































































































 employing data obtained from the Illumina methylation array (the same 
methodology in use for the diagnostic brain tumor classifier
33
) has also shown promise. The 
method with the most prospective clinical trial validation is qMS-PCR. However, one 
retrospective study employing various methods on the same set of TMZ-treated 
glioblastomas suggested that pyrosequencing might actually provide the best stratification in 
terms of outcomes, although this needs to be validated by other independent studies.
62
 Due to 
the large number of assays available and differences in cutoffs for calling methylation, there 
is a nontrivial amount of inter-laboratory heterogeneity, and better harmonization of MGMT 
promoter methylation testing is critically needed. In addition, approximately 10% of patients 
fall into a “gray zone’ with tumors that are neither truly methylated or unmethylated but 
appear to derive some benefit from TMZ.
64
 Immunohistochemistry has been proven to be 




Diagnosis and Imaging 
Most glioblastomas are diagnosed following symptomatic presentation due to their rapid 
expansion and displacement, or infiltrative destruction of brain structures. Suggestive 
symptoms may include new onset epilepsy, progressive headaches, focal neurological signs, 
and mental status alterations in combination with signs of increased intracranial pressure.
66
 
Contrast-enhanced magnetic resonance imaging (MRI) is the diagnostic tool of choice for 
glioblastoma. These tumors typically manifest as an enhancing, necrotic-appearing mass 
surrounded by non-enhancing signal abnormalities consisting of edema and infiltrative tumor 
(Figure 4). Hemorrhage, cystic changes, or multicentric enhancement are also frequently 
present.
67
 When combined with the clinical history, radiological diagnosis of glioblastoma is 


































































































































including metastasis, some lower grade gliomas, and occasionally lymphoma can share 
similar imaging findings. Non-neoplastic neurological conditions, such as abscess or 
demyelinating lesions, may also have a similar appearance. MRI also provides essential 
anatomical details of the tumor and its adjacent brain structures for surgical planning. For 
tumors located close to eloquent locations, functional MRI can help plan optimal surgical 
trajectory and achieve safe maximal resection of enhancing tumor with the goal to improve 
patient survival.
68,69
 For clinical trials, the standardized brain tumor imaging protocol is 
recommended to reduce variability and increase reliability.
70
 Ideally this protocol would also 
be incorporated into routine clinical imaging of glioblastoma patients. 
Advanced MRI techniques are increasingly available to assist in the diagnosis of 
glioblastoma by evaluating their physiological or metabolic properties. Perfusion-weighted 
imaging such as dynamic susceptibility contrast MRI (DSC-MRI) measures cerebral blood 
volume (CBV), an imaging marker that correlates with microvessel density and area. 
71,72
 
(Figure 4) Since microvascular proliferation due to tumor-induced angiogenesis is a hallmark 
of glioblastoma,
73
 CBV may allow differentiation of glioblastoma from other tumor types 
74-
76
 or histological grades.
77
 DSC-MRI may also be useful for differentiation of 
pseudoprogression in response to radiotherapy and immunotherapies from true progression, 
although both false negative and false positive studies may occur.
78,79
 Apparent diffusion 
coefficient (ADC), derived from diffusion weighted MRI, inversely correlates with tumor cell 
density. 
80,81
 ADC values for glioblastomas are lower than for lower grade glioma
82
 but 
higher than for lymphoma.
83,84
 (Figure 4c) Magnetic resonance spectroscopy (MRS) can 
detect alterations of metabolite concentrations within the tumor;
85
 glioblastomas typically 
show markedly elevated choline due to increased cell proliferation and reduced N-acetyl 






































































































































Positron emission tomography (PET) can also provide additional information about 
biology, differential diagnosis, delineation of tumor extent for surgical and radiotherapy 
treatment planning and post-treatment surveillance (progression versus 
pseudoprogression).
86,87












(Figure 5) However, the lack of insurance coverage currently limits the widespread 
incorporation of these studies into standard clinical practice in the United States. 
Accurate determination of response and progression remains a challenge. Currently, 
the Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas is the 
most widely used standard in clinical trials for glioblastoma.
89,90
 These criteria use two-
dimensional tumor measurements and provide guidance on evaluating pseudoresponse, non-
enhancing progression and pseudoprogression. More recently, modifications to the RANO 
criteria have been suggested using a post-radiotherapy baseline,
91,92
 and confirmation of 
progression on subsequent scans has been advised, especially for agents associated with 
pseudoprogression, to ensure that patients are not removed from therapies prematurely. This 
schema also lowers the possibility that patients with spontaneously improving 
pseudoprogression would be offered salvage options or placed inappropriately on clinical 
trials for presumed progressive disease.
91,93
 Additional work is needed to improve response 
assessment for glioblastomas, with first reports on automated volumetric measurements and 






































































































































Medical Management and Supportive Care 
Corticosteroids, preferably dexamethasone (in conjunction with gastric protection if used at 
high doses), are given to reduce symptomatic peritumoral vasogenic edema.
96
 
Dexamethasone alleviates neurological deficits and signs of increased intracranial pressure 
such as headache and drowsiness. Low doses (e.g. 4 mg/day given in 1-2 doses) are effective 
in most clinically symptomatic patients without signs of herniation.
97,98
 There is no need to 
give dexamethasone four times a day.
98
 Side effects of dexamethasone worsen with increased 
dose and duration of treatment.
99,100
 There is also growing evidence that corticosteroids may 
have an adverse effect on patient outcome, so they should be avoided if patients are not 
symptomatic.
101
 For patients on chronic corticosteroids (≥ 20 mg prednisone equivalents 




Seizures affect 23% of glioblastoma patients at presentation
103
 and an additional 20% 
later in the disease course. While patients with seizures require antiepileptic drugs (AEDs), 
studies have not clearly shown a benefit of prolonged primary AED prophylaxis in patients 
who have never had a seizure.
104,105
 Current guidelines recommend tapering AEDs 1-2 weeks 
after surgery and avoiding long-term prophylaxis.
106
 There is no role for primary 
perioperative prophylaxis (i.e. in patients who have never had a seizure). A meta-analysis of 
six studies,
107
 a Cochrane systematic review,
108
 and a subsequent randomized trial of 
phenytoin versus no prophylaxis
109
 have all shown no significant benefit from primary 
prophylaxis. When AEDs are used, newer agents including levetiracetam and lacosamide are 
preferred over older drugs because of generally more favorable side effect profiles, reduced 
laboratory monitoring requirements, and lack of drug-drug interactions.
110
 Emerging data 
suggesting that neurons and glioma cells form synapses via α-amino-3-hydroxy-5-methyl-4-


































































































































receptors, such as perampanel, may be beneficial not only in controlling seizures, but also 
through possible anti-glioma activity.
111,112
 However, a prior trial with another glutamate 
inhibitor, talampanel, was ultimately interpreted to be negative.
113
 
  Venous thromboembolism (VTE) risk is high in the perioperative period and persists 
well beyond, with one-year incidence of approximately 20%,
114,115
 mandating a low threshold 




 though not all
118
 studies suggest the risk of 
precipitating intratumoral hemorrhage with anticoagulants is acceptably low, even in patients 
receiving bevacizumab.
119
 The preferred anticoagulant is not well studied in brain tumors; in 
systemic cancer low molecular weight heparin (LMWH) is preferred over warfarin.
120
 Direct 
oral anticoagulants (DOACs) (factor Xa and thrombin inhibitors) have been reported to be 
safe in patients with brain tumors.
121
 However, no randomized data is available for glioma 
patients and randomized trials on secondary prophylaxis of VTE with DOACs enrolling 
cancer patients have generally shown a similar or slightly higher efficacy than LMWH but 
with a slightly higher risk of bleeding.
122,123
  
A high incidence of recurrent VTE with inferior vena cava (IVC) filters limits their 
use to patients with recent intracranial surgery, intratumoral hemorrhage, or absolute 
contraindications to anticoagulation.
110
 Prophylaxis with IVC filters outside of the 
perioperative setting has not been definitively studied, as the only trial addressing this issue 
was prematurely terminated for slow accrual.
124
 A meta-analysis of pooled randomized 
clinical trial data indicated no survival benefit from anticoagulation in glioblastoma patients, 
but rather suggested that VTE should be treated more vigorously in this patient population.
125
 
Cognitive deficits, personality changes, and mood disturbances are major 
comorbidities for glioblastoma patients.
96
 Before treatment, up to 91% of brain tumor patients 
have cognitive deficits, with only moderate correlation with cognitive complaints.
126,127
 The 




































































































































Medical treatment with acetylcholinesterase inhibitors (donepezil) or psychostimulants 
(methylphenidate, modafinil) to prevent cognitive decline and fatigue after radiotherapy in 
patients with brain tumors (<50% were glioblastoma) have been unsuccessful.
130-133
 Although 
the 6-month prevalence of clinical depression is about 20% in brain tumor patients,
134
 
randomized studies on medical treatment are lacking.  
Regular exercise,
135
 adoption of a healthy diet, avoidance of hyperglycemia,
136
 early 
discussion of goals of care and involvement of palliative care should be considered. Despite 
extensive interest in ketogenic diets and cannabinoids, there is currently no clinical data 
supporting their routine use. 
 
Standard Therapy 
Despite recent advances in our understanding of glioma biology, the prognosis of patients 
with glioblastoma remains poor. With standard-of-care consisting of surgery, radiotherapy, 
and TMZ chemotherapy, median overall survival (OS) in well-selected patients in clinical 
trials is approximately 15-18 months,
58,59,137
 and 5-year survival is less than 10%.
138
 Once 
glioblastomas recur, median OS is estimated to be 24–44 weeks.139-141 Standard-of-care 
therapies for patients with newly diagnosed glioblastoma are summarized in Table 2, Figure 
6 and recurrent glioblastoma in Table 3, Figure 7. Because none of these treatments are 
curative, the National Comprehensive Cancer Network (NCCN) recommends clinical trials as 
the preferred option for eligible patients.
142
 Treatment must also be tailored to the individual 
based on age, functional status, goals of care, etc. Integration of palliative care early in the 
course of the illness is important, and best supportive care may be the most appropriate 





































































































































Surgical procedures should be tailored to individual patients, taking into consideration 
indications, risk-benefit ratio, and prognostic impact for each patient. In the past, tumor 
extent has been mostly defined on MRI by T1-weighted sequences with contrast 
enhancement, however, non-contrast enhancing tumor volume has to be incorporated as well 
into the target volume for resection.
143
 Whenever microsurgical resection is deemed to be 
high risk based on the patient’s medical condition and/or the functional topography or 
eloquence of the affected brain region, a stereotactic or open biopsy should be performed to 
obtain at least a histological and molecular diagnosis.
66
 In order to obtain sufficient material 
for histological diagnosis and grading, the surgeon aims to target and biopsy areas of solid 
tumor mass that contain viable tumor cells, preferably avoiding necrotic areas or adjacent 
nonneoplastic brain. The most frequently requested genetic markers (IDH1/2 mutation and 
MGMT promoter methylation) appear to be present homogeneously throughout the tumor, so 
the risk of a sampling error by obtaining a "false-negative" result or misclassification of the 
molecular profile is relatively low.
144
 However, since additional molecular markers may gain 
clinical relevance in the future, multiple (larger) samples should be considered for more 
advanced genomic analyses. Whenever possible, areas of enhancement must be included in 
the target for the biopsy to ensure accurate WHO grade classification of the tumor. Extent of 
resection should be verified by an early postoperative contrast enhanced MRI, preferably 
within 48 hours after surgery.
143
 
Radical microsurgical resection of a glioblastoma is limited by the highly invasive 
nature of the tumor with infiltrating tumor cells typically extending significant distances from 
the main tumor mass.
145
 Nevertheless, the goal for glioblastoma surgery should be gross total 
resection of the enhancing solid tumor mass whenever feasible. While some studies report 







































































































































 The goal is to leave the smallest amount of residual 
postoperative enhancing volume possible as this correlates with survival.
153
 Current standard 
surgical adjuncts include stereotactic navigation systems using anatomical and functional 
MRI datasets, intraoperative MRI, ultrasound, intraoperative functional monitoring, and the 
fluorescent dye 5-aminolevulinic acid (ALA) to visualize vital tumor tissue, all of which are 
increasingly used to improve and maximize the extent of resection while reducing the risk of 
new neurological deficits (Figure 8).
147,154,155
 As a general principle, preventing new 
permanent neurological deficits is more important than maximizing the extent of resection, 
because glioblastomas are not cured by surgery alone, while recognizing and taking into 
consideration the benefits of maximal safe resection. Postoperative deficits due to emerging 
complications are a negative prognostic factor.
156,157
 This emphasizes the relevance of a risk-
adapted concept which embeds surgery into a thorough prognostic evaluation. Given the 
complexities of surgery for glioblastoma, consideration should be given to referring patients 
to high-volume centers specializing in the care of brain tumor patients. 
Biodegradable polifeprosan 20 with carmustine wafers inserted at the time of surgery 
are approved by the United States Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) for the treatment of both newly-diagnosed high-grade glioma and 
recurrent glioblastoma.
158,159
 They were shown to produce a modest survival advantage of 
approximately 2 months but are used only sporadically, in part because the efficacy data stem 
from the pre-temozolomide era, carmustine from the wafers has limited brain penetration, 
safety and tolerability are an issue in low-volume centers, and this treatment may preclude 



































































































































Post-Surgical Management of Newly-Diagnosed Glioblastoma 
Following maximal safe resection, the generally accepted treatment for glioblastoma is 
radiotherapy (RT) with concurrent TMZ (75 mg/m
2
/day x 6 weeks) and maintenance TMZ 
(150-200 mg/m
2
/day x 5 days for six 28 day cycles). 
58,138
 (Figure 6) Because MGMT 
promoter methylation status is predictive of the efficacy of TMZ,
49
 TMZ can be withheld in 
select patients with MGMT unmethylated tumors where the benefit of TMZ is minimal, 
especially in the context of clinical trials,
61
 or when the risks of TMZ outweigh the benefit 
(i.e., toxicity limits TMZ use). During adjuvant TMZ, the addition of tumor treating fields 
(TTF), which provide low intensity, intermediate frequency (200 kHZ), alternating electric 
fields to produce antimitotic effects selective for dividing tumor cells with limited toxicity, 
extended survival by a median of 4.9 months in one study.
160
 Neither dose-dense TMZ 
regimens,
59
 extending the length of adjuvant TMZ treatment beyond 6 cycles,
161-163
 nor the 
addition of bevacizumab,
137,164
 yield additional survival benefit.  
A recent small randomized phase III trial examined the benefit of an intensified 
lomustine-TMZ regimen for newly diagnosed MGMT promoter methylated glioblastoma. 
When combined with radiotherapy, median OS increased from 31.4 months with standard 
TMZ to 48.1 months with lomustine-TMZ.
165
 Since the sample size was small 
(approximately 70 patients in each arm), the survival curves separated late (after 2-3 years), 
and in univariate analysis the effect was small, the role of this regimen remains unclear.
166
 
Hematologic toxicity was greater in the lomustine-TMZ arm, and fewer patients were able to 






































































































































Most standard approaches recommend delivering radiotherapy (RT) in the range of 60 Gray 
(Gy) in 30 fractions of 2 Gy, based on targets selected using the immediate post-surgical 
MRI. The recommendation of the European Organization for Research and Treatment of 
Cancer (EORTC) is to perform RT in a single phase (60 Gy, 2 Gy per fraction) while the 
Radiation Therapy Oncology Group (RTOG) approach uses an initial larger volume defined 
by the FLAIR abnormality plus a 2-cm margin, which receives 46 Gy, in 23 fractions of 2 Gy 
each, plus additional 14 Gy given to the resection cavity and residual enhancing tumor.
167
 
Great attention is paid to limit exposure of structures that are at risk of radiotherapy-induced 
damage, including ophthalmic and optic structures, brainstem, cervical cord, cochlea, and, 
where feasible, temporal lobes and/or hippocampi.
168
 A number of institutions have published 
modifications of this approach, in an attempt to decrease the volume of normal brain 
irradiated.
169
 There remains considerable disagreement regarding the optimum RT volume 
and margin expansions and advanced imaging has not yet helped resolve this issue.
169,170
 
Several ongoing research efforts are focusing on better defining the volume that truly needs 
to be boosted to a higher dose by incorporating advanced imaging such as perfusion/diffusion 
MR, MR spectroscopy, and amino-acid PET, but these remain investigational. Prior dose-
escalation efforts have largely failed, but these were conducted in the pre-temozolomide era, 
and current trials are investigating whether radiotherapy dose-escalation might be beneficial, 
at least in some patients, when combined with temozolomide (e.g. NCT02179086). It is also 
unclear whether modern RT techniques will yield superior outcomes (Figure 9). For 
example, emerging data suggest that the reduction in the low dose volume to normal brain 
decreases therapy-associated lymphopenia,
171
 and this has been suggested to be indirectly 






































































































































Radiochemotherapy can produce transient worsening of contrast enhancement on MRI for 
several months in approximately 10-30% of patients, sometimes associated with symptoms of 
intracranial mass-effect.
173,174
 A similar problem may occur with immunotherapies. The 
diagnosis of pseudoprogression can be problematic; DSC-MRI,
78,79
 and amino-acid PET 




Because of the difficulty in differentiating 
pseudoprogression from progression, the RANO working group has recommended avoiding 
enrolling patients within 3 months of completion of radiochemotherapy into clinical trials for 
recurrent disease, unless the recurrence is mainly outside the radiotherapy field or there is 
tissue confirmation of progression.
175
 However, histopathological distinction of ”residual 
tumor” (apparently dormant and damaged) versus truly “recurrent tumor” (healthier and 




Since the median age of glioblastoma is 65 years, a significant number of patients are 
considered “elderly.”1 Their treatment represents a particular challenge, as they generally 
have a worse prognosis and are less tolerant of toxicities.
177
 There is evidence that 
hypofractionated RT (40 Gy/15 fractions of 2.67 Gy over 3 weeks) is as effective as the 
standard 60 Gy over 6 weeks.
178
 An international phase III trial of newly diagnosed 
glioblastoma patients age 65 and older demonstrated an overall survival (OS) advantage with 
hypofractionated RT (40 Gy/15 fractions of 2.67 Gy ) with TMZ, compared to RT alone (9.3 
vs. 7.6 months), with clinical benefit predominantly in patients with methylated MGMT 
promoter.
179
 However, there has never been a direct comparison of hypofractionated RT with 
TMZ compared to the standard 6 weeks of RT with TMZ.  For patients with poor functional 


































































































































depending on the MGMT promoter methylation status. In both the NOA-08
180
 and the Nordic 
Clinical Brain Tumor Study Group trials
181
 which compared RT vs. TMZ, RT was more 
effective than TMZ for MGMT promoter-unmethylated tumors, whereas TMZ was more 
effective than RT for MGMT promoter-methylated tumors. Radiotherapy schedules used in 
the elderly population include 40 Gy delivered in 15 fractions,
178
 34 Gy in 10 fractions,
181
 or 
25 Gy in 5 fractions,
182
 although the role of the latter regimen is more controversial. 
Recurrent Glioblastoma 
Glioblastoma patients invariably recur after a median interval of less than 7 months,
58
 and 
there is no clear standard-of-care salvage therapy (Figure 7). NCCN guidelines list clinical 
trials as the preferred option for eligible patients.
142
 Surgery may have a role for symptomatic 
and/or large lesions. However, only patients who undergo complete resections have any 
survival benefit.
152
  Other options include systemic therapy such as temozolomide 
rechallenge, nitrosoureas, or bevacizumab, re-irradiation, TTF (in the US),
183
 none of which 
have been shown to prolong survival in  randomized trials in this setting, or palliative care for 
patients with poor performance status.  
Bevacizumab  
Multiple studies of the humanized vascular endothelial growth factor (VEGF) antibody 
bevacizumab for glioblastoma have failed to demonstrate a survival benefit.
137,164,184
 
However, bevacizumab is often effective in reducing peritumoral edema and related clinical 
symptoms and signs.
185
 It is approved in the United States and some other countries, but not 
in the European Union, for use in recurrent glioblastoma due to improvement in progression-
free survival (PFS), and reduction in corticosteroid use.
184
 Continuation of bevacizumab post 
progression did not improve outcome in a small study.
186
 Patients with recurrent glioblastoma 


































































































































exclude prior use of bevacizumab. Bevacizumab has also been proven to be effective in 
radiation-induced necrosis, although the doses used are lower than standard dosing for 




Temozolomide (TMZ) Rechallenge 
Rechallenge with TMZ may be reasonable, especially in patients with MGMT promoter 
methylated glioblastoma that relapse more than few months after completion of maintenance 
TMZ in the first-line setting.
188,189
 The uncontrolled RESCUE study observed that patients 
who lived longest with dose-dense TMZ were those that progressed after a treatment-free 
interval.
189
 While MGMT status was not predictive of outcome in the RESCUE study, the 
DIRECTOR trial did demonstrate increased time to treatment failure with TMZ rechallenge 
in patients with MGMT promoter methylated versus unmethylated tumors.
188
 However, there 
is no evidence to suggest that TMZ rechallenge is superior to nitrosoureas in any patient 
population. 
Nitrosoureas  
Nitrosoureas, including lomustine (CCNU), carmustine (BCNU) and fotemustine, have good 
blood-brain barrier penetration.
190
 Fotemustine is available in some European countries, but 
has not been approved for use in the United States. Lomustine is generally preferred over 
carmustine given its oral formulation, schedule of administration, and better safety profile. In 
several phase III randomized trials, the lomustine monotherapy arm (dosed as 6 week cycles 
of 100-130 mg/m
2
 for up to 6 cycles) was associated with median OS of 7.1-8.6 months and 
progression-free survival (PFS) of 1.5-3 months.
184,191
 Data from these trials also suggest that 
patients with MGMT-methylated tumors are more likely to benefit from nitrosoureas than 





































































































































Although other chemotherapeutic agents such as irinotecan, carboplatin, procarbazine and 
etoposide are sometimes used for patients with recurrent glioblastomas, there is no data 
suggesting that they are beneficial.
142
 A recent randomized phase II trial suggested that 
regorafenib, a VEGF receptor 2 and multikinase inhibitor, increased survival in patients with 




Repeat RT in the form of radiosurgery or hypofractionated radiotherapy (30-35 Gy in 5-15 
fractions) is increasingly used for recurrent glioblastoma, although there is currently no 
definitive data regarding benefit.
195,196
 A secondary analysis of NRG Oncology/RTOG 0525 
trial showed no significant survival benefit of re-irradiation over systemic therapy after tumor 
progression.
197
 Preliminary results of the NRG phase II trial comparing bevacizumab alone 
versus bevacizumab with re-irradiation in patients with recurrent glioblastomas showed that 
the addition of re-irradiation improved PFS (7.1 months with the combination versus 3.8 





Given the poor outcomes with current therapies, there is great interest in various experimental 
approaches under investigation.
199




































































































































Targeted Molecular (Precision) Therapies  
Despite advances in understanding the molecular pathogenesis of glioblastoma, there has 
been only modest progress in developing effective targeted molecular therapies.
200
 
Challenges include the paucity of agents that effectively cross the blood brain barrier,
22
 the 
relative lack of “easy” targets such as BRAFV600E mutations, redundant signaling 
pathways,
28
 and tumor heterogeneity.
19,36,42
 
The 2016 update of the WHO classification incorporated molecular parameters into 
the definition of certain brain tumors.
201
 Several of these markers are easily assessed by 
immunohistochemistry, including IDH1R132H, and Histone H3 K27M, while other point 
mutations can be determined by sequencing. BRAF V600E mutation status, while challenging 
by immunohistochemistry, is easily assessed by sequencing, and has therapeutic implications 
for a subset of glioblastoma patients. For more comprehensive profiling, targeted next-
generation-sequencing (NGS) panels have proven to be useful, while some centers also have 
the capacity to perform whole exome sequencing (WES) or whole genome sequencing 
(WGS). Microsatellite instability can be readily assessed by either genome-wide or medium-
sized panel approaches, and is relevant given the tumor-agnostic approval by the FDA for 
pembrolizumab for microsatellite instability (MSI)-high cancers. Copy number variations, for 
example, the aforementioned chromosomal +7/-10 pattern, are relevant for glioma diagnosis 
and possibly treatment. Fusion detection, to identify potentially relevant and druggable group 
of alterations (for example fusions of the neurotrophic-tropomyosin receptor tyrosine kinase 
(NTRK fusions)), requires specific coverage by either DNA-based approaches or alternatively 
mRNA-based analyses. Routine examination of these (and potentially additional) alterations 





































































































































Examples of putative treatment-predictive biomarkers exist. The most often 
investigated biomarkers, high level EGFR amplification or the EGFRvIII mutation, have 
been targeted with and without tumor pretesting, with the aim of suppressing pathway 
activation with EGFR inhibitors such as erlotinib,
203
 targeting the heterogeneously expressed 
EGFRvIII neoantigen by vaccination with a peptide vaccine, rindopepimut, 
204
 or using the 
conformational change for specific binding of an antibody-drug conjugate, depatuxizumab 
mafodotin (ABT414)
205-208
 without clinical activity.
209
 Targeting BRAFV600E mutations 
showed responses to monotherapy with RAF inhibitors such as vemurafenib,
210
 or dual 
therapy with combined BRAF/MEK inhibition with trametinib and dabrafenib,
211
 but these 
mutations are rare in glioblastoma except for epithelioid glioblastoma,
212
 a somewhat 
controversial entity likely to be often confused with pleomorphic xanthoastrocytoma. Other 





FGFR mutations and FGFR3-TACC3 fusions, 
216
 are all uncommon in glioblastoma. Of note, 
mutations in the telomerase reverse transcriptase (TERT) promoter ,  are found in up to 85% 
of glioblastomas,
217
 although to date this mutation has been challenging to target. 
The lack of success in targeted therapy trials in glioblastoma is likely due to tumor 
heterogeneity, lack of knowledge of the contribution of genetic alterations to tumor 
maintenance, targeting subclonal or unstable genetic alterations instead of stable and clonal 
oncogenic drivers, redundant signaling pathways, use of archival instead of freshly obtained 
recurrent tumor tissue for biomarker testing, insufficient assessment of drug brain tumor 
concentrations, failure of target inhibition, and development of rapid secondary resistance 
and clonal selection.  
Currently, most therapeutic strategies and biomarkers are focused on single or 
multiple biological features that are differentially detected in patient groups responding to a 


































































































































that may have benefited from experimental treatments, but in the absence of validation, these 
remain only hypothesis-generating. For example, proneural subtype of glioblastoma defined 
by expression analyses 
218,219
 or MRI features
220
 may derive benefit from the addition of 
bevacizumab to standard treatment. Lower levels of CpG2 promoter methylation of CD95 
ligand (CD95L) were correlated with improved overall survival with the CD95 inhibitory 
treatment asunercept (APG101) in combination with re-irradiation compared to re-irradiation 
alone.
221
 Also, based on a retrospective analysis, mTOR Ser2448 phosphorylation may be a 
putative predictive biomarker of response to the mTOR inhibitor temsirolimus plus radiation 
in patients with newly diagnosed glioblastoma lacking MGMT promoter methylation.
222
 
Others have suggested PTEN loss predicts benefit from mTOR inhibitors.
223
 Without 
preselection, mTOR inhibition is not only ineffective, but may even confer a survival 
disadvantage compared to the standard-of-care. For example, the addition of a different 
mTOR inhibitor everolimus did not provide any advantage in an unselected group of patients 
with newly diagnosed glioblastoma irrespective of MGMT status.
224
 (Table 4) 
Several ongoing clinical trials are based on well-defined molecular characteristics of 
the tumor, confirmation of adequate drug penetration and biological efficacy (e.g., target 
engagement and modulation in neoadjuvant, “window-of-opportunity” surgery-based 
trials),
223,225
 as well as necessary retrospective validation of potential biomarkers (Table 5). 
Several large clinical trials are underway where prospectively assigned biomarkers will 
enrich pre-defined patient cohorts for potentially benefiting patients. The Nationale Centrum 




), a trial of molecularly matched 
targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without 
MGMT promoter methylation is currently ongoing.
226
 Similarly, the National Cancer Institute 
(NCI)-MATCH trial, while designed mainly for extra-cranial solid tumors, does allow 







































































































































 and the GBM Adaptive, Global, Innovative Learning 
Environment (AGILE) consortium are taking a different approach by enrolling patients into 
unselected cohorts with given therapies first, assessing potential biomarkers as the trial 
accrues and integrating this information via adaptive randomization processes to enrich 
specific arms that may be showing benefit with particular biomarkers (Table 5).
228
 
The extensive tumor heterogeneity in glioblastoma suggest that combination therapy 
may be more effective than treatment with single agents. However, combination studies to 
date have been associated with little activity and often significant toxicity, and increase the 
need for assessment of the targets in the tumor.
200,229
 Potentially, combinations of more 
potent selective agents with less off-target effects may be better tolerated. To address the 
issues of heterogeneity and redundant signaling pathways, there is significant interest in 
exploiting synthetic lethality, targeting tumor stem cells,
230
 or common downstream pathways 




Figure 10 shows selected targeted molecular therapies evaluated in recently 
completed or ongoing trials. 
 
Targeting DNA Damage Response (DDR) Pathways  
The most effective non-surgical treatments for glioma are DNA-damaging agents, including 
radiotherapy (RT) and cytotoxic chemotherapy.
58
 Enhancing their effect in tumor while 
sparing normal tissue is an appealing strategy that is particularly relevant in tumors such as 


































































































































in glioblastoma, which appears to have a significant stem cell compartment in which DNA 
repair is up-regulated and contributes to treatment resistance.
232,233
 
The complex signaling and effector events following DNA damage, often referred to 
as the DNA damage response (DDR), are summarized in Figure 11 and have been reviewed 
recently.
234-236
 DNA double-strand breaks (DSB) are the main toxic lesion induced by DNA 
damaging agents, but single strand breaks (SSBs) are also now recognized as important 
lesions for lethality. Unrepaired SSBs are thought to stall replication forks, which may 
indirectly contribute to the DSB load, particularly in the context of replication stress. 
Combining DNA damaging agents with DDR inhibitors will increase the levels of unrepaired 
DSBs and SSBs in cells, and thus has the potential for significant chemo- and radio-
sensitization. However, specific DDR inhibitors, such as PARP inhibitors, induce 
myelosuppression when given with DNA damaging agents, potentially limiting their use in 
combination with TMZ. As such, it will be important to identify glioma-associated molecular 
biomarkers (e.g., tumor mutations not found in normal tissue), which could allow the 
administration of active, but safe drug combinations. 
Multiple DDR inhibitors are now being tested in clinical trials for glioblastoma 
(summarized in Table 6). Recent studies have elucidated important links between intrinsic 
DNA repair defects and sensitivity to specific DDR inhibitors in glioblastoma, which likely 
will serve as key molecular biomarkers for patient selection in these trials. Loss of MGMT 
protein expression is a possible predictor for TMZ sensitivity, and emerging data suggests it 
may also be an important biomarker for TMZ-based combinations with inhibitors of poly 






































































































































Targeting Tumor Metabolism 
In the past decade there has been converging data to support tumor metabolism as a 
key determinant of glioma progression. Oncogenic mutations modulate glioblastoma 
metabolism to promote survival, proliferation and evasion of therapy, in addition to tumor 
micro-environmental factors influencing glioblastoma metabolism.
20,241
 Data suggest that 
regulators of glioblastoma metabolism can be used as prognostic, diagnostic and therapeutic 
tools that can advance management of glioblastoma.
20
 There is also growing evidence that 
tumor genotype and the brain’s biochemical and cellular microenvironment shape the 
metabolic reprogramming of glioblastoma cells, generating vulnerabilities that could be 
exploited therapeutically.
20
 (Figure 12) 
A classic and recognized biochemical adaptation in glioblastomas, as with other solid 
cancers is the metabolic shift to aerobic glycolysis rather than mitochondrial oxidative 
phosphorylation, regardless of oxygen availability, a phenomenon referred to as the “Warburg 
Effect.”20 Targeting genes that regulate tumor metabolism can be ideal candidates for rational 
drug design. Some of the regulators involved in glioblastoma have been shown to be PTEN 
Induced Kinase1 (PINK1)
242
 and Hexokinase 2 (HK2),
243
 where inhibition of HK2 and 
activation of PINK1 in pre-clinical models have shown therapeutic benefit in glioblastoma. 
Similarly, cholesterol metabolism may be a therapeutic target in certain glioblastomas. In 
EGFR driven tumors, there is high dependency on cholesterol uptake, rendering the 







































































































































Unlike several other solid tumors, no breakthrough has been achieved with current 
immunotherapy strategies for glioblastoma.
21,245
 Although the concept that relieving glioma-
associated immunosuppression to allow immune-mediated anti-tumor responses is attractive 
and has received preclinical experimental support,
246-251
 clinical trials testing this hypothesis 
using targeted therapies such as transforming growth factor-beta (TGF-β) 252 or colony 




 or more recently, immune 
checkpoint blockade with the anti-program cell death protein 1 (PD1) antibody nivolumab in 
recurrent and newly-diagnosed MGMT unmethylated glioblastoma, as well as other agents 
were unsuccessful.
21,245,254
 (Table 7) However, that does not necessarily imply that attempts 
to improve outcome with immunotherapy approaches may not be effective, as appropriate 
target inhibition in the glioma microenvironment or even immunogenicity assessments were 
largely lacking, and read-out was mainly limited to classical efficacy endpoints. As more is 
learned about the role of the tumor microenvironment in immunotherapy responses, it may be 
possible to enrich for select glioblastoma patient subsets that respond to specific 
immunotherapy regimens. 
It has become evident that glioblastoma is an immunologically “cold” tumor 
characterized by a paucity of tumor infiltrating effector lymphocytes.
18,21
 In understanding 
mechanisms of immune resistance, we have evolved from the three “E” hypothesis of 
elimination, equilibrium, and escape.
255
 Hence to reconcile this concept of “hot” and “cold” 
tumors with the three “E’s” hypothesis, we must also consider the magnitude of a tumor’s 
adaptive and intrinsic resistance.
18
 Factors that drive intrinsic resistance for glioblastoma 
include a paucity of neoantigens (most glioblastomas have low mutational burden relative to 
other cancers) and active inhibition including the release of soluble immunosuppressive 


































































































































and indolamine 2,3 dioxygenases (TDO/IDO) and arginase, which deplete tryptophan and 
arginine and result in the accumulation of metabolites such as kynurenine leading to 
suppression of T cell activity.
18,21,256
 Furthermore, there is data to suggest that location ( i.e. 
having a tumor in the brain) negatively influences the immune system globally by actively 
deleting antigen specific T-cells
257
 and potentially sequestering them in the bone marrow.
258
 
Glioblastoma induces adaptive resistance by promoting exhaustion of infiltrating T-cells
259
 
and recruiting suppressive myeloid cells and regulatory T-cells.
18,245
 In addition, the 
corticosteroids frequently used in these patients also contribute to immunosuppression and 
impair the efficacy of immunotherapies.
260-262
  
The immunologically “cold” microenvironment of glioblastoma tumors likely 
contributed to the negative phase III studies of the PD1 antibody nivolumab in patients with 
recurrent (CheckMate-143)
21,254
 and MGMT unmethylated, newly diagnosed (CheckMate-
498) glioblastoma. Hence current strategies are focusing on overcoming both intrinsic and/or 
adaptive resistance. Efforts to enhance effector immune infiltrate into the microenvironment 







 are being developed to meet this challenge (Table 8).  
Sporadic partial and complete responses with immune checkpoint blockade among 
patients with hypermutated tumors due to germline DNA repair deficits suggest that these 
tumors likely exhibit low innate resistance and they possess immunologically relevant 
mutations including tumor specific neoantigens or tumor-associated antigens that the immune 
system can recognize and attack.
269,270
 However, the numbers of mutations alone may not be 
sufficient to generate an immune response. Roughly 10% of patients may develop 
hypermutated tumors at recurrence after  TMZ chemoradiotherapy,
36,271
 and an 8% response 
rate was seen in the CheckMate-143 study with nivolumab in recurrent glioblastoma.
254
 Yet, 


































































































































firm assumptions that hypermutation was indeed associated with response; in fact, the 
immunogenicity and clonality of mutations, not just their quantity, may determine 
responsiveness to immunotherapy.
272
 Furthermore, the negative phase III study of 
rindopepimut,
204
 an EGFRvIII peptide vaccine, argues that targets must be present and stably 
expressed in all tumor cells or that targeting multiple tumor antigens may be important. 
Current approaches to overcome intrinsic resistance have revolved around novel antigen 
identification strategies by targeting multiple overexpressed and private mutations derived 
from next generation sequencing
260,268,273
 and mass-spectrometry analysis of the HLA 
ligandome. Whereas peptide-based approaches targeting these antigens have been successful 
in eliciting systemic as well as local antigen-specific CD8 responses, the limited magnitude 
of the response may benefit from other potentially augmentative strategies such as transgenic 
T cell receptors, combinations with appropriate checkpoint-inhibitors or other measures 
targeting the suppressive myeloid compartment.
21,245
  
Approaches to overcome adaptive resistance for glioblastoma initially focused on 
checkpoint molecules.
21,245
 This approach has not been successful for at least two key 
reasons: first, intratumoral T-cells are severely exhausted with loss of effector function and 
hence these cells appear to not be rescuable with immune checkpoint inhibitor therapy and 
second, myeloid cells including macrophages and/or microglia are programmed by 
glioblastomas to be highly suppressive in the tumor microenvironment.
18,250
 Therapies such 
as oncolytic viruses that can activate macrophages from an M2 to an M1 phenotype, induce 
antigen presentation, and promote migration of antigen presenting cells to regional lymph 
nodes, may overcome some of these obstacles.
266
 However, it should be noted that since 
macrophages exist in complex activation continuums the situation is likely to be more 
complicated.
274
 Combination approaches with local therapies such as stereotactic 
radiosurgery,
247,248
 laser ablation (NCT03277638) and local chemotherapy
275


































































































































potential means to overcome the adaptive resistance of glioblastomas. Another interesting 
approach is the concept of neoadjuvant anti-PD-1 treatment administered prior to planned 
debulking surgery. Two recent studies demonstrated favorable modulation of local immune 
reactivity in recurrent glioblastoma patients using such an approach.
276,277
 An improved 
outcome in one of these studies,
276
 as well as encouraging benefit in other solid tumors 
including significant rates of pathologic response,
278,279
 suggest that further evaluation of 
neoadjuvant checkpoint administration in glioblastoma is warranted.  
There is also growing interest in cellular therapies, especially chimeric antigen 
receptor (CAR) T-cells, and more recently, CAR-transduced natural killer cells. CAR T cells 
have been engineered to express molecules on their surface called chimeric antigen receptors, 
which allow them to recognize and bind to specific antigens on tumor cells, leading to target 
cell killing in an HLA-independent manner.
280
 Although one patient with leptomeningeal 
spread of glioblastoma responded to treatment with CAR T-cells against IL13R2,263 the 
experience with CAR T cells to date for glioblastoma has been generally disappointing.
264,280
 
Current efforts are focused on developing next generation CAR T-cells directed against 
multiple antigens, designing them to induce epitope spreading, combining them with 
checkpoint inhibitors or conventional therapies such as radiotherapy to help overcome 





There has been resurgent interest in oncolytic viruses (OV) and gene therapy (GT) in clinical 
trials for glioblastoma.
266
 Oncolytic viruses are either natural viral strains or genetically 
engineered viruses designed to infect and/or replicate selectively in tumor cells.
283,284
 Gene 


































































































































anticancer cDNAs. With either therapy there is an initial phase of direct cytotoxic activity 
caused by OV replication or the GT-delivered anticancer cDNA. This cytotoxicity may then 
induce a second phase of innate and adaptive antitumor immunity caused by released tumor 
antigens.
285
 There is one OV (talimogene laherparepvec) that has been FDA-approved for 
melanoma
286
 and several GTs have been approved since 2017, such as Voretigene 
neparvovec (Luxturna) for blindness and Onasemnogene abeparvovec (Zolgensma) for spinal 
muscular atrophy.  
 For glioblastoma, several phase 1 clinical trials of both OV and GTs are in progress or 
have been completed, usually in the recurrent setting.
287,288
 In most, the treatment is delivered 
by intratumoral injection at the time of surgery. Currently there are several open GT trials 
(see clinicaltrials.gov) that include: 1) injection in the resected recurrent glioblastoma cavity 
of an adenoviral GT vector that delivers an interleukin 12 cDNA whose transcription is 
activated by an oral agent, veledimex (NCT03636477);
262
 and 2) injection into the resected 
newly diagnosed glioblastoma cavity of an adenoviral vector that delivers a thymidine kinase 
cDNA that leads to cytotoxicity when subjects take the oral drug, valacyclovir, combined 
with chemoradiation (NCT03576612).
289
 Both trials also entail neoadjuvant or adjuvant 
immune checkpoint inhibition to counteract T cell dysfunction. The latter trial is also being 
tested in pediatric brain tumors. Currently open OV trials in patients with recurrent 
glioblastoma include: 1) stereotactic injection of an oncolytic HSV1 (oHSV) that delivers an 
interleukin 12 cDNA (NCT02062827): 2) stereotactic injection of an oHSV that has been 
engineered to replicate better in glioblastoma cells that express the stem cell marker, nestin 
(NCT03152318); and 3) monthly injections of oHSV G47∆.290 There are also trials delivering 
OV with stem cells: 1) intra-arterial delivery of allogeneic bone marrow-derived human 
mesenchymal stem cells loaded with the oncolytic adenovirus DNX-2401 (BM-hMSCs-


































































































































adenovirus in to newly-diagnosed glioblastoma (NCT03072134). A general conclusion is that 
both OV and GT treatments have been well tolerated. When post-tissue treatment is 
available, there has been evidence of increased infiltration of immune cells, including 
cytotoxic T cells that also may have up-regulated inhibitory immune checkpoint signaling.
291
 
More advanced trials (Phase 2 and beyond) are also ongoing mostly for OVs in the 
recurrent glioblastoma setting. These include: 1) convection-enhanced delivery of an 
engineered poliovirus (PVSRIPO; NCT02986178);
292
 2) stereotactic injection of an oncolytic 
adenovirus with selectivity for glioblastoma cells driven by the p16/RB pathway and integrin 
expression (Tasadenoturev; DNX-2401) in combination with pembrolizumab 
(NCT02798406);
293
 and 3) intracavitary injection after glioblastoma resection of a retrovirus 
that delivers a cytosine deaminase cDNA that provides chemosensitivity to 5-fluorocytosine 
(Toca 511; NCT02414165).
265,294
 However, the phase III trial of Toca 511 was recently 
reported to show no survival benefit compared to standard-of-care in patients with recurrent 
glioblastoma.
295
 A phase III trial of another viral therapy, ofranergene obadenovec (VB-
111) that targets tumor endothelium also failed to show a survival advantage in combination 
with bevacizumab compared to bevacizumab alone,
296
 although it is possible that the 
simultaneous administration of bevacizumab may have impeded the effects of the virus.
296,297
 
Therefore, while there is currently optimism in the pursuit of novel concepts, this optimism 
must also be coupled with ongoing efforts to find molecular and immunologic variables and 





































































































































Overall, almost 100 therapies are under evaluation for glioblastomas. In addition to the ones 
listed above, other treatments include cytotoxic agents such as Val 083 (NCT02717962), 
BAL101553 (NCT03250299) and agents that may augment the activity of TMZ such as 
ibudilast (NCT03782415). 
 
Improving Clinical Trial Design 
An important factor limiting the development of more effective therapies for glioblastoma is 
the slow and inefficient clinical trial process. Frequently glioblastoma patients are excluded 
from phase I oncology trials evaluating novel agents without sound rationale.
298
 As 
glioblastoma patients are generally healthy,
299
 greater inclusion of these patients in phase I 
oncology trials will facilitate the identification of novel agents for further testing at an earlier 
stage. 
Since the ability of many agents to cross the blood-brain barrier to achieve therapeutic 
tumor concentrations and inhibit the appropriate molecular pathways adequately is either 
unknown or inadequate, there is a need for more “window-of-opportunity” “phase 0” surgical 
trials early during drug development. In these studies patients receive a therapeutic agent for 
1-2 weeks prior to surgery and tumor from both enhancing and non-enhancing areas obtained 
at surgery are analyzed for drug concentrations and pharmacodynamic effects. There is a 
need to develop more efficient clinical trial networks focused on these studies to identify 
agents worthy of further development. 
Most treatments in glioblastoma have been initially assessed in uncontrolled single-
arm studies using PFS or OS compared to contemporary or historical controls as primary 


































































































































compared to external control data from prior trials
300
 and commonly, the failure to develop a 
biomarker to enrich patient populations in parallel or to inform on likelihood of success or 
failure of a new treatment. These shortcomings led to several inadequate phase II to III 













 Moreover, the frequent failure to understand 
why these trials were unsuccessful prevented lessons that could be learned to inform the 
design of future trials. No single therapeutic biomarker, not even MGMT promoter 
methylation, has been uniformly applied despite evidence that even TMZ only benefited 
approximately a third of patients with glioblastoma.
49
 Beyond that, it seems unlikely today 
that there are new treatment options that would be active in an all comer trial, reinforcing the 
need for more elaborate research efforts prior to embarking on large clinical trials. 
Steps to increase the likelihood of a drug to be successful in glioblastoma include 
preclinical modeling and “window-of-opportunity (phase 0) surgical assessment, the parallel 
(and mandatory) assessment of tissue, cerebrospinal fluid or blood for biomarkers and 
molecular imaging that may aid in enriching for benefiting versus failing patients, and the use 
of active, randomized control groups in earlier stages.
300
 Innovative clinical trial concepts are 
based on the idea that phase II clinical evaluation must have a control arm, but could add 
several experimental arms. The endpoints of such trials might be pharmacodynamic 
biomarker-based or mainly imaging-based, relying on more advanced MRI (or PET) 
techniques, including artificial intelligence algorithms, 
94,95
 and allow termination or 
expansion of cohorts in a dynamic fashion based on their likelihood of success. If biomarker-
based, adaptations may take place on the basis of quick, prospectively assessed biomarkers 
that are correlated to patients’ performance with a given treatment and allow enrichment for 
subsequent biomarker-positive patients with the same therapy. Examples of this approach are 
GBM AGILE (NCT03970447)
228
 and INSIGhT (NCT02977780).
227


































































































































the assignment of patients to a specific therapy based on real-time assessment of a panel of 
biomarkers to be tested, or even on high throughput molecular tumor characterization, to 
allow (theoretically) treatment in the group of greatest likelihood of success, as done in 
N2M2 trial (NCT03158389).
226
 These trials are most efficiently performed with multiple 
experimental groups and one standard arm. The basic requirements are a recent, non-
historical tissue sample, adequate tests and assignment algorithms, and a broader tumor board 
including biomarker/bioinformatics specialists.  
The only randomized effort so far to evaluate the value of treatment allocation based 
on molecular testing over standard-of-care, the French SHIVA trial,
304
 comes from the non-
neuro-oncology area and failed to demonstrate overall benefit using historical tissue 
information guiding treatment decisions at progression. Nonetheless, there are many options 
to improve on this important first effort. One example is the WINTHER trial which tested the 
role of the tumor transcriptome in identifying tumor vulnerabilities that may be treated with 
targeted therapies, an approach that may expand data-driven therapeutic options for 
patients.
305
 While such modern clinical trial concepts are innovative and promising, the risk is 
that most glioblastomas are not a single pathway-driven disease and therefore will not be 
amenable to singe agent targeted therapy selected based on molecular profiling. 
As the design of clinical trials improves it will also be important to consider 




































































































































Challenges and Future Directions 
Despite decades of research into the biology and treatment of glioblastoma, many challenges 
remain to treat this universally lethal cancer (Figure 13). Glioblastomas are particularly 
aggressive and treatment refractory resulting in disproportionate mortality as reflected in the 
fact they account for only 1.4% of cancers but 2.9% of cancer-related deaths. 
306
  
A major impediment to improving outcome is the fact that currently only 
approximately 11% of newly-diagnosed glioblastoma patients enroll in clinical trials.
307
 
Reasons for this deficiency were recently reviewed and include many factors including lack 
of knowledge regarding availability of trials
308
 and the fact that physical or cognitive 
symptoms may reduce ability or willingness to travel for patients diagnosed in the 
community and seeking clinical trials at academic centers. Indeed, a survey of 57 patients 
demonstrated that travel time below 1 hour was significantly (4X) associated with increased 
willingness to consider clinical trial participation. 
309
 Developing strategies to improve 
clinical trial accrual will be critical.
308
 Overly strict eligibility criteria are another barrier to 
accrual and efforts are underway to address this.
310
 
There are many other challenges that need to be addressed to improve therapy for 
patients with glioblastoma. A key consideration is the CNS location of these tumors and the 
need to consider treatment related neurologic toxicities (e.g. radiotherapy induced 
neurocognitive injury or accelerated atherosclerotic disease)
311
 which may profoundly impact 
quality of life. Another critical consideration is the blood-brain barrier (BBB). Glioblastomas 
reside in and intertwine with the brain, where these tumors exploit the brain’s natural defense 
mechanism against toxins via the BBB.
22,312
 The BBB is composed of endothelial cells linked 
by tight junctions against a basement membrane that are surrounded by pericytes and 
astrocyte foot processes.
22


































































































































lipid-soluble molecules. The vast majority of drugs do not possess these properties and 
therefore do not cross the BBB to a significant degree.
313
 In addition to the physical barrier, 
the BBB is also reinforced with ATP-binding cassette transporter family proteins—drug 
efflux transporters on the luminal side of the BBB that remove toxic metabolites, xenobiotics, 
and drugs from the brain.
22,313
 Together, these components prevent 98% of all small 
molecules from crossing the BBB.
313
 Although it is well recognized that portions of 
glioblastoma tumors can have a leaky, compromised BBB, significant regions of the tumor 
(often the infiltrative tumor edge left behind in the patients after resection) still have an intact 
BBB and impede effective drug delivery.
22,312
 With many recent major clinical trials failing 
to improve survival due to the compounds not achieving therapeutic concentrations at the 
target site,
314
 the issue of brain penetration remains a major challenge to the treatment of 
glioblastoma. Strategies to overcome this issue include the development of significantly more 
agents with good BBB penetration,
315
 hijacking endogenous influx transporters such as low-
density lipoprotein receptor-related protein 1 (LRP1),
316
 inhibiting efflux pumps, cell 
mediated drug delivery, convection-enhanced delivery, and focused ultrasound and 
microbubbles to transiently disrupt the BBB.
22,317
 
Another critical therapeutic challenge for glioblastoma is the high degree of inter- and 
intra-tumoral heterogeneity. As the first cancer to be characterized by The Cancer Genome 
Atlas (TCGA), glioblastoma has been shown to have multiple different genetic drivers.
28
 The 
differences among glioblastomas are further complicated by the existence of intra-tumoral 
heterogeneity at both molecular and functional levels. For example, different regions within 





 and/or proliferation kinetics.
318,319
 While the impact of this intra-
tumor heterogeneity on therapeutic outcome remains poorly characterized, preclinical 


































































































































compared to more differentiated counterparts) within a tumor can have differential responses 
to TMZ 
318,319
 or ionizing radiation,
233
 which may underlie resistance to these conventional 
treatments. Additional work is necessary to examine the impact of glioblastoma heterogeneity 
to more contemporary therapies, including molecularly targeted therapies and 
immunotherapies. For example, comparison of tumor specimens obtained at diagnosis and at 
recurrence suggest that temporal heterogeneity may occur with certain genetic alterations 
such as EGFRvIII mutations which are lost in 30-60% of recurrent tumors.
36,42,204
 This raises 
the possibility that rebiopsy and genotyping, and/or improvements in minimally invasive 
liquid biopsy technology,  may be necessary for therapies directed at targets that change over 
time. 
In addition to the differential intrinsic drug sensitivity across distinct glioblastoma cell 
subpopulations, glioblastoma cells also display remarkable plasticity as a means to 
circumvent the toxic effects of cancer therapy. In response to targeted tyrosine kinase 
inhibitors, glioblastoma has been shown to adapt and survive through a wide variety of 
mechanisms, including the dynamic regulation of extrachromosomal DNA, chromatin 
remodeling to a slow-cycling/drug-tolerant persistent state, suppression of PTEN tumor 
suppressor, and reactivation in oncogenic signaling pathways (e.g., PI3K or RAS-MAPK 
signaling).
223,320,321
 This redundancy in restoring oncogenic signaling flux can manifest via 
receptor tyrosine kinase (RTK) switching
322
 or the co-activation of multiple RTKs,
323
 both of 
which can maintain persistent oncogenic signaling to promote tumor viability. Although there 
have been some examples of benefit with targeted molecular therapies (dabrafenib and 
trametinib for glioma with BRAFV600E mutations,
211
 and entrectinib and larotrectinib for 
NTRK fusions,
213
 and possibly ONC201 for H3K27M mutations),
214,215
 most targeted 
therapies have failed because of low BBB penetration of the drugs employed, redundant 


































































































































combinations thus requiring suboptimal dosing. Alternative combination approaches, such as 
those that target orthogonal signaling/functional networks to induce synthetic lethality in 
glioblastoma,
321,324
 are potential options to augment drug responses to therapies against the 
primary genetic driver. A likely corollary to these advanced approaches is that an approach 
based on a single mutation matched with a putative targeted therapy is unlikely to work in 
most glioblastomas, and efforts to integrate multiplatform molecular analyses (gene 
expression, copy number changes, immune cell/pathway profiling) are going to be required in 
future clinical trial designs to utilize advanced enriching strategies and maximize what we 
can learn even when specific therapeutic agents are not efficacious in a glioblastoma patient 
population 
Although immunotherapy holds great promise as a new treatment option for 
glioblastoma, the negative results in large randomized studies to date 
21,204,254
 indicate the 
increased complexity and difficulty in achieving a clinically meaningful immune therapy 
effect in glioblastoma. In fact, it appears glioblastoma provides challenges in almost every 
area of the cancer immunity cycle including limited antigenicity, impaired antigen 
presentation, intrinsic and therapy induced systemic immune suppression and a unique 
immune suppressive microenvironment.
18
 A functional and mechanistic understanding of 






































































































































Although there has been important progress in understanding the molecular pathogenesis and 
biology of glioblastoma, this has not translated into significantly improved outcomes for 
patients. While much remains to be learned, important therapeutic strategies have been 
identified that are being translated clinically. In addition to developing novel therapies based 
on strong scientific rationale, there is a need to increase the efficiency with which they are 
evaluated in clinical trials. This includes greater inclusion of glioblastoma patients in phase I 
oncology trials, an expanded network for conducting “window-of-opportunity” “phase 0” 
surgical studies to assess blood-brain barrier penetration and pharmacodynamic effects, 
greater incorporation of molecular imaging and blood and CSF biomarkers, integration of a 
broad range of molecular biomarkers into clinical trial schema, more efficient design of 
clinical trials and significantly increased trial accrual. These changes will hopefully lead to 
the identification of more effective therapies for patients with glioblastoma. 
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Mode of Inheritance Phenotypic features Associated brain tumors 




syndrome type 2 
Dominant Development of multiple 
adenomatous colon polyps (>100), 
predisposition to colorectal cancer, 
and brain tumors 
Medulloblastoma, glioma 





Progressive cerebellar ataxia, 
susceptibility to infections, 





neural system tumor 
syndrome (155755) 
Dominant Predisposition to malignant 









Development of intraosseous 
benign cartilaginous tumors, cancer 
predisposition 
Glioma 




Development of multiple 
adenomatous colon polyps (<100), 
predisposition to colorectal cancer, 
and brain tumors 
Medulloblastoma, glioma, 





Dominant Predisposition to gastrointestinal, 
endometrial and other cancers 



































































































































MSH2,MLH1,MSH6,PMS2 Mismatch repair 
deficiency syndrome 
(276300) 
Recessive Pediatric cancer predisposition; 
café-au-lait spots; colon polyps 
Glioma 
NF1 (17q11.2) Neurofibromatosis 1 
(NF1) (162200) 
Dominant Neurofibromas, Schwannomas, 
café-au-lait macules 
Astrocytoma, schwannomas, 
optic nerve glioma 
RB1 (13q14) Retinoblastoma Dominant  Development of multiple tumors of 





TP53 (17p13.1) Li-Fraumeni 
syndrome (151623) 
Dominant Predisposition to numerous 
cancers, especially breast, brain, 
and soft-tissue sarcoma 






Dominant Development of multi-system non-
malignant tumors 
Giant cell astrocytoma 
 
Abbreviations used: ATM= Ataxia Telangiectasia; APC= Adenomatous polyposis coli; CDKN2A= cyclin-dependent kinase Inhibitor 2A; IDH1= 
Isocitrate dehydrogenase 1; IDH2= Isocitrate dehydrogenase 2; MLH1= MutL homolog 1, colon cancer, nonpolyposis type 2; MSH2= MutS 
protein homolog 2; MSH6= MutS protein homolog 6; NF1= Neurofibromin 1; PMS2= PMS1 homolog 2, mismatch repair system component; 








































































































































Table 2: Selected Phase III Clinical Trials in Patients with Newly Diagnosed Glioblastoma  










Median PFS / 
EFS (months) 
Randomized phase 





diagnosed GBM  
Age 18-70 years 










irradiation in daily 
fractions of 2 Gy 
given 5 days per 
week for 6 weeks, for 
total of 60 Gy 
TMZ 75mg/m2/day 
during radiation from 
the first to the last day 
of RT (up to 49 days) 
followed by 6 cycles of 
adjuvant TMZ 150-200 
mg/m2 for 5 days 
during each 28 day 
cycle) 
RT alone: 12.1 
(95% CI, 11.2-13.0) 
RT + TMZ: 14.6 
(95% CI, 13.2-16.8) 
Unadjusted HR for 
death 0.63; 95 % CI, 
0.52-0.75; P<0.001  
RT alone: 5.0 
(95% CI, 4.2-
5.5) 




label trial of 












N/A Adjuvant TMZ as per 
Stupp regimen above 
TTF initiated 4-7 
weeks from last day of 
TMZ alone: 15.6  
TMZ + TTF 20.5  
HR 0.64; 99.4% CI, 
0.42-0.98; P = .004 







































































































































Age ≥ 18 years 







RT until second 
progression or for a 
maximum of 24 
months 
95%CI, 0.52-
0.76; P < .001 
Studies in MGMT methylated GBM 
Randomized, open-
label, phase III trial 






diagnosed GBM  
Age ≥ 18 years 















field RT to total dose 
of 59–60 Gy in 30–33 
single day fractions 
Standard concurrent + 
adjuvant TMZ as per 
Stupp above 
Lomustine-TMZ: 6-
week cycles of 
lomustine 100 mg/m² 
on Day 1 and TMZ 
100-200 mg/m² on 
days 2–6 for up to 6 
cycles, starting in the 
first week of RT 
In modified 
intention to treat 
population –  
Standard TMZ: 31·4 
months (95% CI, 
27·7–47·1)  
Lomustine-TMZ: 
48·1 months (95% 
CI, 32·6 months–
not assessable)  




intention to treat 
population –  
Standard TMZ: 






HR 0·91; 95% 
CI 0·57–1·44; 
p=0·4113 
Studies in elderly patients (≥ age 65 years) 
Randomized phase 
III trial of 
hypofractionated RT 
Newly 
diagnosed GBM  






administered in 15 
TMZ 75mg/m2/day 
during radiation from 
the first to the last day 
RT alone: 7.6 
RT + TMZ: 9.3 HR 
0.67 for death; 95% 
RT alone: 3.9 
RT + TMZ: 5.3  


































































































































+/- TMZ (N=562) 
179
 
ECOG PS ≤ 2 
Deemed by their 
physicians not to 
be suitable to 
receive 




daily fractions over a 
period of 3 weeks, for 
total of 40.05 Gy 
of RT (21 consecutive 
days) followed by 
adjuvant TMZ 150-200 
mg/m2 for 5 days 
during each 28 day 
cycle) for up to 12 
cycles 




death; 95% CI, 












Age ≥ 65 years 











administered in 30 
daily fractions over 
6-7 weeks, total 60.0 
Gy 
TMZ 100 mg/m2 for 1 
week on, 1 week off 
TMZ: 8·6 (95% CI, 
7·3–10·2)  
RT: 9·6 months 
(95% CI, 8·2–10·8) 
HR 1·09, 95% CI 
0·84–1·42, pnon-
inferiority=0·033 
TMZ: 3·3 (95% 
CI, 3·2–4·1) 
RT: 4·7 (p5% 
CI, 4·2–5·2) 






III trial of TMZ vs. 






diagnosed GBM  
Age ≥ 60 years 








RT: 34·0 Gy 
administered in 3·4 
Gy fractions over 2 
weeks 
Standard RT: 60·0 
Gy administered in 
2·0 Gy fractions over 
6 weeks 
TMZ 200 mg/m² for 5 
days during each 28 
day cycle for up to six 
cycles 
In comparison 
with standard RT: 
6·0 months (95% 
CI, 5·1–6·8) 
TMZ: 8·3 months;  
HR 0·70; 95% CI 
0·52–0·93, p=0·01 
Hypofractionated 




































































































































6·5–8·6), HR 0·85; 





CI: confidence interval 
ECOG: Eastern Cooperative Oncology Group 
EFS: event free survival  
HR: hazard ratio 
KPS: Karnofsky performance status 
OS: overall survival 
PFS: progression-free survival 
PS: performance status 
RR: radiographic response rate 
RT: radiotherapy 
TMZ:  TMZ 



































































































































Table 3: Selected Clinical Trials of Systemic Agents in Patients with Recurrent Glioblastoma  













Randomized phase III trial 
of lomustine +/- 
bevacizumab in recurrent 
GBM 
437 with recurrent 




Lomustine: 8.6  





Lomustine: 1.5  















Nonrandomized, phase II 
trial of continuous TMZ 50 
mg/m2 daily for recurrent 
GBM 
Recurrent GBM at 
first progression 
Group B1: 33 with 
early progression 
during the first 6 
cycles of adjuvant 
TMZ 
Group B2: 27 with 
progression on 
adjuvant TMZ 
beyond standard 6 
cycles but before 
completing of 
adjuvant TMZ 




NR Group B1: 3.6  
Group B2: 1.8  













































































































































TMZ (treatment free 






Randomized, phase II trial 
of two different dose-
intense TMZ regimens 
(note trial prematurely 
closed due to withdrawal of 
support) 
Recurrent GBM at 
first progression 
randomized to  
Arm A: TMZ 120 
mg/m2 one week on, 
one week off 
Arm B: TMZ 80 
mg/m3 three weeks 
on, one week off 
Arm A: 9.8  
Arm B: 10.6 
Arm A: 1.8  





Arm A: 8% 
Arm B: 16% 
 
Abbreviations: 
CI: confidence interval 
EORTC: European Organisation for Research and Treatment of Cancer 
HR: hazard ratio 
NR: not reported 
OS: overall survival 
PFS: progression-free survival 
RR: radiographic response rate 
TMZ:  TMZ 



































































































































Table 4: Selected Completed Trials with Targeted Molecular Therapies 
Molecular 
Target 









Basket trial with recurrent 
glioma arm 
 ORR 25% 
overall 
 3/6 GBM had SD 
as best response 
BRAFV600E 
mutation 






Phase II basket trial using 
novel Bayesian hierarchical 
statistical design 
 ORR in GBM 
29%; duration of 
response > 12 
months in over 











Randomized phase III trial in 
newly diagnosed GBM with 
EGFR amplification comparing 
RT + TMZ +/- DM 
 639 patients 
randomized 
 Ocular toxicity 
common 
  DM MS 18.9 
(17.4, 20.8) 
 Placebo: 18.7 
(17.0, 20.3) 












Randomized phase II in 
recurrent GBM comparing 
DM, DM + TMZ, or TMZ 
alone 
 260 patients 
 25-30% grade 3 
or 4 ocular 
toxicity 
 Hazard ratio 
(HR) for the 
combination arm 
DM+TMZ 
compared to the 
TMZ was 0.71, 
95% CI [0.50, 









































































































































control was 0.66 
(95% CI = 0.48, 
0.93), p = 0.017.   
 Efficacy of DM 
monotherapy was 
comparable to 
that of TMZ (HR 
=1.04, 95%CI 
[0.73, 1.48]; p = 
0.83)  
Exportin 1 Important for transport of 
tumor suppressor proteins 
and oncoprotein mRNA 
from nucleus to cytoplasm 
Selinexor NCT0198634
8 
Multiarm phase II trial in 
recurrent GBM 
 ORR 10% 
 PFS6 19% 






Highly oncogenic FGFR 
mutations and FGFR-
TACC gene fusion that 
confers sensitivity to 





Phase I/II study in patients 
recurrent glioma positive for 
FGFR fusion 





Highly oncogenic FGFR 
mutations and FGFR-
TACC gene fusion that 
confers sensitivity to 








Phase II study in recurrent 
GBM with FGFR1-TACC1, 
FGFR3-TACC3 fusion and/or 
activating mutation in FGFR1, 2 
or 3 
 26 patients 
 ORR 7.7% 
 4 patients disease 













































































































































Randomized phase II trial of 
RT+TMZ+/- everolimus in 
newly-diagnosed GBM 
 171 patients 
 No difference in 
PFS (median PFS 
8.2 m for 
everolimus vs 
10.2 m for 
control; P = 0.79) 
 OS for 
everolimus was 
inferior to that 
for control 
patients (median 
OS: 16.5 vs 21.2 
m, respectively; 
P = 0.008) 
mTOR  Temsirolimus NCT0101943
4 
Randomized phase II of 
RT+TMZ versus RT + 
temsirolimus in newly-
diagnosed unmethylated GBM 
 111 patients 
randomized 
 Not difference in 
1year survival 
(72.2% in TMZ 
arm; 69.6% in 
the temsirolimus 





tumor (HR 0.13; 








































































































































ol 3-kinase (PI3K)  
 
PIK3CA or PIK3R1 mutati
on, loss of PTEN activity 
through PTEN mutation, 
homozygous deletion or 
negative PTEN expression 
(< 10% of tumor cells that 














arm, phase II trial in patients 
with PI3K pathway-activated 
glioblastoma at first or second 
recurrence 
 ORR= 0 
 PFS6 8% 









Phase III placebo-controlled 




 Median PFS 
longer in the 
bevacizumab 
group than in the 
placebo group 
(10.6 months vs. 
6.2 months;HR 
0.64; P<0.001).  












Phase III placebo-controlled 
trial comparing RT + TMZ +/- 
bevacizumab 
 637 patients 
randomized 
 No difference in 
OS (bevacizumab 
median, 15.7 m, 
control 16.1 m 
(HR 1.13) 













































































































































Phase III trial comparing 
lomustine to lomustine + 
bevacizumab in recurrent GBM 
 437 patients 
randomized 




 Median OS 9.1 m 
with lomustine 
compared to 8.6 
m in combination 
group (HR 0.95) 
 PFS 4.2 m with 
bevacizumab + 
lomustine 
compared to 1.5 
m with lomustine 
alone (HR 0.49; 
P<0.001) 
VEGF receptors 
1, 2, and 3 and 
PDGF receptors 
 




Randomized phase II 
comparing regorafenib with 
lomustine in patients with 
relapsed glioblastoma(REGOM
A): a multicentre, open-label, 
randomised, controlled, phase 2 
trial. 
 
 7·4 months (95% 
CI 5·8-12·0) in 
the regorafenib g
roup and 5·6 
months (4·7-7·3) 
in the lomustine 
group (hazard 














Single arm phase II in recurrent 
GBM 
 220 patients 
 Bevacizumab 
naïve 14.5-17.6% 








































































































































Lower levels of 
methylation of the CpG2 


























CAN008 Biomarker CD95 
Ligand and CpG2 methylation 
in Chinese patients with GBM 
 
 Progression-free 
survival at 6 
months (PFS-6) 
rates were 3.8% 
[95% confidence 
interval (CI), 0.1-
19.6] for rRT and 
20.7% (95% CI, 
11.2-33.4) for 
rRT+APG101 (P 





Abbreviations: GBM, glioblastoma; HR, hazard ratio; mTOR; mammalian target of rapamycin; m, months; ORR, objective response rate; SD, 














































































































































Phase 0/I  P53 wildtype status  
 Phase 0/I to measure 
concentrations in tumor in 
patients With recurrent GBM 
and of AMG 232 in 
combination with RT in patients 
with newly diagnosed GBM and 







Phase 0  No selection 
 Phase 0 to evaluate tumor PK 
and PD effects 
Recurrent GBM NCT02133183 
CDK4/6 Abemaciclib 0/II  Patients with activation of 
CDK4/6 pathway and intact RB 
Recurrent GBM NCT02981940 
CDKs 1, 2, 7 







 Phase I with metronomic TMZ 
followed by randomized phase 
II comparing zoltiraciclib 
=TMZ versus TMZ 
Recurrent grade III 
glioma and GBM 
NCT02942264 
CDKs 1, 2, 7 





I  Zotiraciclib + RT for 
unmethylated MGMT patients 
 Zotiraciclib with TMZ for 
methylated MGMT patients 
 Zotiraciclib alone for recurrent 
patients 
Newly diagnosed and 
recurrent grade III 












II  H3K27M mutated gliomas 
 Non H3K27M mutated midline 
GBM 
Recurrent H3K27M 






































































































































(IL-4) receptor of genetically engineered IL-4 
linked to a modified version of 
the Pseudomonas aeruginosa 
exotoxin A 
HIF2alpha PTC2977 II  No selection Recurrent GBM NCT02974738 
Proteasome Marizomib III  No selection Newly-diagnosed GBM NCT03345095 





















 Umbrella trial N2M2/NOA-20 
 Alk expr 
 P53wild-type/MDM2 high 
 SHH activation 
 CDK4/6 high or co-deletion of 
CDKN2A/B 
 Phospho mTOR Ser 24448 













































Abbreviations: GBM, glioblastoma; mTOR; mammalian target of rapamycin; MDM2, mouse double minute 2; m, months; ORR, objective 









































































































































Current Clinical Trials Testing DDRi's in Glioma 
Targe
t 






















Veliparib, RT, and 
TMZ  
Newly diagnosed glioma, Ages 





OPARATIC 1 Olaparib and TMZ Recurrent GBM, Adults Completed Chalmers - 
PARADIGM 1/2 







Olaparib and RT Newly diagnosed GBM, Adults 
Recruiting 














Study 104  1/2 
BGB290 with RT 




BGB290 with TMZ 
Recurrent IDH1/2-mutant 






BGB290 with TMZ 
Recurrent IDH1/2-mutant 











1 AZD1390 and RT 
Newly diagnosed and recurrent 
GBM, Adults Recruiting Wen 
NCT0342
3628 









































































































































AZD1775, TMZ and 
RT 
Newly diagnosed and recurrent 






Monotherapy Rec rrent GBM, Adults Completed Sanai 
NCT0220
7010 




































































































































Table 7: Selected Completed Trials with Immunotherapies (Including Viral Therapies) 
Vaccines Type Phase  Trial Trial result 
 
ICT107 (dendritic cell vaccine 
against MAGE-1, HER-2, AIM-








NCT01280552  124 patients randomized 
 PFS increase d by 2.2 months (P=0.011) 
 OS increased by 2.0 months (NS) 
 HLA-A2 subgroup showed increased clinical 
benefit and immune response 
Rindopepimut (EGFRvIII 








NCT01480479  745 patients randomized 
 No difference in outcome with addition of 
rindopepipimut 
 Median overall survival was 20·1 months 
(95% CI 18·5-22·1) in 
the rindopepimut group versus 20·0 months 
(18·1-21·9) in the control group (HR 1·01, 
95% CI 0·79-1·30; p=0·93) 
 







Phase III  NCT00045968  331 patients treated 
 Primary endpoint of PFS not reported 
 90% crossover at progression 
 Median OS was 23.1 months from surgery 
Checkpoint Inhibitors Type Phase  Trial Trial result 
 




Recurrent GBM III NCT02017717  369 patients randomized 
 No difference in outcome between the 
nivolumab or bevacizumab arm 
 Median OS was 9.8 months with nivolumab 
and 10.0 months with bevacizumab (NS), 
and the 12-mo OS rate was 42% in both 
arms.  
 Median PFS was 1.5 months for nivuolumab 
and 3.5 months for bevacizumab ORRs were 
8% for nivolumab and 23% for bevacizumab 


































































































































methylation were associated with longer OS 
in the nivolumab arm versus the 
bevacizumab arm 






Recurrent GBM I  NCT02197169  37 patients 
 Fairly well-tolerated 
 20% of patients survived > 3 years 
 12% response 
 Evidence of virus replication in tumor 
 Cases of pseudoprogression 
Polio virus (PVSRIPO)
292
 Recurrent GBM 1 (Convection 
enhanced 
delivery) 
NCT01491893  61 patients enrolled 
 Dose level −1 (5.0×107 TCID50) was 
identified as the phase 2 dose 
 19% of the patients had a PVSRIPO-related 
adverse event of grade 3 or higher 
 OS reached a plateau of 21% (95% 
confidence interval, 11 to 33) at 24 months 
that was sustained at 36 months 
Ad-RTS-hIL12 (adenovirus 
producing IL-12) + velidimex
262
 
Recurrent GBM 1  
 
NCT03679754  31 patients 
 Fairly well tolerated but cytokine syndrome 
observed in some 
 Median OS=12.7 months  
 Inflammatory responses seen in recurrent 
tumors 
 Concurrent corticosteroids negatively 
affected survival: Patients cumulatively 
receiving >20 mg versus ≤20 mg of 
dexamethasone (days 0 to 14), median OS 
was 6.4 and 16.7 months, respectively 
Gene Mediated Cytotoxic 
Immunotherapy (GMCI; AdV-






II NCT00589875  48 patients 
 No dose-limiting toxicities 
 Median OS was 17.1 months for GMCI + 



































































































































 Greatest benefit was observed in gross total 
resection patients: median OS of 25 versus 
16.9 months (P = .0492)  
TOCA 511 (replication 
competent retrovirus which 
transduces tumor cells with the 
cytosine deaminase gene) in 
combination with TOCA FC (5-





Recurrent GBM II/IIII NCT02414165  403 patients treated 
 Fairly well tolerated 
 No difference in primary endpoint of OS 
between TOC 511 and lomustine (HR=1.06 
(95%CI: 0.83, 1.35; p-value=0.6154) 
 Median OS: Toca 511: 11.07 months 
 SOC 12.22 months 
 Durable response rate 2.5% with TOCA 511; 
4.5% with SOC (NS) 
 
 
GBM; glioblastoma; NS, not significant; OS, overall survival; PFS, RT, radiotherapy; progression-free survival; SOC, standard-of-care; Tk, 






































































































































Table 8: Examples of Ongoing Trials With Immunotherapies 
Vaccine 
 
Tumor Type Phase  Trial 
Personalized neoantigen cancer vaccine with RT and 
pembrolizumab 
Newly diagnosed unmethylated GBM I NCT02287428 
Personalized neoantigen DNA vaccine in combination with 
immune checkpoint blockade therapy 
Newly diagnosed unmethylated GBM I NCT03068832 
Personalized neoantigen- based vaccine in combination with 
nivolumab and ipilimumab 
Newly-diagnosed unmethylated GBM I NCT03422094 
Personalized peptide vaccine in combination with standard 
therapy and TTFields 
Newly-diagnosed GBM I NCT03223103 
pp65 CMV RNA-Pulsed Dendritic Cells With Tetanus-
Diphtheria Toxoid Vaccine 
Newly-diagnosed II NCT02465268 
SurVaxM (peptide vaccine against survivin) with TMZ 
following RT and TMZ 
Newly-diagnosed GBM II NCT02455557 
INO-5401 (DNA plasmids targeting Wilms tumor gene-1 (WT1) 
antigen, prostate-specific membrane antigen (PSMA) and human 
telomerase reverse transcriptase (hTERT) genes) and INO-9012 
(DNA plasmid expressing IL-12) in combination with 
cemiplimab (REGN2810), with radiation and chemotherapy 
Newly-diagnosed GBM I/II NCT03491683 
VXMO1 (Attenuated Salmonella typhi Ty21a carrying a plasmid 
encoding for vascular endothelial growth factor receptor 
(VEGFR)-2) + avelumab 
Recurrent GBM I NCT03750071  
CMV vaccine VBI-1901 Recurrent GBM I NCT03382977 
CMV pp65 peptide DC vaccine in combination with nivolumab Recurrent GBM I NCT02529072 
Pembrolizumab and ATL-DC (dendritic cell tumor lysate) 
vaccine 
Recurrent GBM I NCT04201873 
EO2401, Multipeptide Vaccine, With and Without Check Point 
Inhibitor 
Recurrent GBM I/II NCT04116658 
IMA950/Poly-ICLC + pembrolizumab Recurrent GBM I/II NCT03665545 
CMV RNA- loaded DC vaccine +/– anti- CD27 therapy 
varlilumab (to deplete Treg cells) 
Recurrent GBM II NCT03688178 
WT1 peptide vaccine (DSP-7888) in combination with 
bevacizumab  
Recurrent GBM II NCT03149003 


































































































































Checkpoint Inhibitors and combinations 
 
Tumor Type Phase  Trial 
Nivolumab + Gene Mediated Cytotoxic Immunotherapy (GMCI; 
Ad-Tk) + valacyclovir + RT + TMZ 
Newly-diagnosed GBM I NCT03576612 
Nivolumab + ipilimumab + short course RT Newly-diagnosed unmethylated GBM I NCT03367715 
Nivolumab, IDO inhibitor (BMS-986205), and RT With or 
Without TMZ 
Newly-diagnosed GBM I NCT04047706 
Pembrolizumab + vorinostat (HDAC inhibitor) with RT and 
TMZ 
Newly-diagnosed GBM I NCT03426891 
Atezolizumab + RT and TMZ Newly-diagnosed GBM I/II NCT03174197 
Nivolumab + TMZ versus TMZ (NUTMEG) Newly-diagnosed elderly GBM II NCT03367715 
Nivolumab + Gliadel wafers Newly-diagnosed GBM II  
RT +/- Nivolumab (CheckMate 498) * Newly-diagnosed unmethylated GBM III NCT02617589 
RT + TMZ +/- Nivolumab (CheckMate 548)# Newly-diagnosed methylated GBM III NCT02667587 
Nivolumab +anti-LAG3 or anti-CD137 Recurrent GBM I NCT02658981 
Avelumab + laser interstitial therapy Recurrent GBM I NCT03341806 
Nivolumab + Ad-RTS-hIL12 (adenovirus producing IL-12) + 
velidimex 
Recurrent GBM I NCT03636477 
Cemiplimab + Ad-RTS-hIL12 + velidimex Recurrent GBM I NCT04006119 
Biomarker driven therapy using immune activators with 
nivolumab (Nivolumab + anti-GITR (MK4166) or Nivolumab + 
IDO1 inhibitor (INCB024360) or Nivolumab + Ipilimumab 
Recurrent GBM I NCT03707457 
Anti-TIM3 monoclonal (TSR-022) +/– nivolumab Advanced solid tumors I NCT02817633 
Indoximod (IDO inhibitor) and  TMZ Recurrent GBM I NCT02052648 
Neoadjuvant pembrolizumab Recurrent GBM undergoing surgery II NCT02852655 
Pembrolizumab Hypermutated recurrent GBM II NCT02658279 
Nivolumab +ipilimumab Hypermutated recurrent GBM II  
Nivolumab Recurrent IDH mutated glioma II NCT03718767  
Pembrolizumab and  re-irradiation  Recurrent GBM (bevacizumab naïve or 
refractory) 
II NCT03661723 
Nivolumab + standard or low dose bevacizumab Recurrent GBM II NCT03452579 
Nivolumab + ipilimumab + TTF Recurrent GBM II NCT03430791 
Pembrolizumab + DNX-2401 (CAPTIVE) Recurrent GBM II NCT02798406 


































































































































Pembrolizumab + levantinib (VEGFR and multikinase inhibitor) Recurrent GBM II NCT03797326 
Intratumor INT230-6 (amphiphilic cell penetration enhancer 
molecule combined with cisplatin and vinblastine) + nivolumab 
and ipilimumab 
Recurrent GBM + other cancers I/II NCT03058289 
Targeted Therapies and Other Agents 
 
Tumor Type Phase  Trial 
WP1066 (STAT 3 inhibitor) Recurrent GBM and melanoma I NCT01904123 
Cellular Therapies Including CAR T-cells 
 
Tumor Type Phase  Trial 
EGFRvIII CAR T-cells + pembrolizumab Newly-diagnosed EGFRvIII mutated 
unmethylated GBM 
I NCT03726515 
Intracerebral EGFRvIII CAR T-cells (INTERCEPT) Recurrent GBM I NCT03283631 
IL13Ralpha2-Targeted CAR T-cells with or without nivolumab 
and ipilimumab 
Recurrent GBM I NCT04003649 
Memory-Enriched T Cells Transduced to Express a HER2-
Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric 
Receptor and a Truncated CD19 
Recurrent GBM I NCT03389230 
 
GBM, glioblastoma; HDAC, histone deacetylase; VEGFR2, RT, radiotherapy; TMZ, termozolomide; vascular endothelial growth factor receptor 
2; TTF, tumor treating fields 
*Reported to be negative 





































































































































Figure 1.  Glioblastoma (A) Incidence rate per 100,000 persons by age at diagnosis and sex, Central Brain Tumor Registry of the 
United States (CBTRUS) 2012-1016 (50 US states and Puerto Rico included) and (B) 5-year relative survival probability (with 95% 
confidence intervals) by age at diagnosis and sex, National Program of Cancer Registries (NPCR) 2012-2016 (43 US states included). 






































































































































Figure 2: Glioblastomas are characterized by somatic molecular defects in three major processes: initiating tumor growth, evading 
senescence and enabling immortal growth. Genomic abnormalities in each of the three processes appear required for gliomagenesis. 



































































































































Figure 3: The many forms of GBM. (A) Classic GBM, with pseudopalisading necrosis and microvascular proliferation. (B) Giant 
cell GBM. (C) Epithelioid GBM with BRAF V600E. (D) Gliosarcoma. (E) Granular cell GBM. (F) Small cell GBM. All images are 




































































































































Figure 4. 58-year-old with a glioblastoma who presented with gait disturbance. FLAIR (A), T2W (B) and contrast-enhanced T1W (C) 
images show a large, necrotic-appearing, enhancing mass with surrounding T2/FLAIR signal abnormality in the periventricular 
regions crossing corpus callosum.  There is evidence of hypercellularity as evident by low diffusivity on ADC map (D) 









































































































































Figure 5. Contrast-enhanced MRI T1W (left) and 
18
FET-PET (right) of a 42-year-old patient showing much larger extent of a 
glioblastoma on the PET images compared to the enhancing tumor evident by MRI.  The tumor extent on the PET image was 














































































































































































































































































































































































































Figure 8: Microsurgical resection of a right-sided recurrent IDHwt glioblastoma WHO grad IV using intraoperative neuronavigation, 
neuromonitoring and 5-ALA fluorescence techniques. A: T1ce axial, sagittal and coronal planes including DTI fiber tracking (blue 
fibers). The green trajectories / red points represent the pointer for intraoperative neuronavigation. B) Upper image: corresponding 
intraoperative 5-ALA fluorescence image taken from the area as depicted by neuronavigation. Lower image: opening of the right 
ventricle due to critical involvement by tumor formation. C) Postoperative MRI confirms gross total resection without residual 




































































































































Figure 9: This figure shows, from left to right, how the transition from 2D RT to 3D RT to intensity modulated radiotherapy to 
intensity modulated proton therapy harnesses the potential for sparing normal, uninvolved brain substructures from unnecessary RT 




















































































































































































































CDK = cyclin-dependent kinase 
EGF = epidermal growth factor 
EGFR = epidermal growth factor receptor 
FGFR = fibroblast growth factor receptor 
GF = growth factor 
HDAC = histone deacetylase 
HSP = heat shock protein 
MDM2 = murine double minute 2 
mTOR = mammalian target of rapamycin 
PARP = poly(ADP-ribose) polymerase 
PDGFR = platelet derived growth factor receptor 
PKC = protein kinase C 
RTK = receptor tyrosine kinase 
SF/HGF = scatter factor / hepatic growth factor 
TGF- = transforming growth factor beta 
TGFR = transforming growth factor beta receptor 
TrK = Tropomyosin receptor kinase 
VEGF = vascular endothelial growth factor 
VEGFR = vascular endothelial growth factor receptor 


































































































































Figure 11: A simplified overview of signaling from common types of DNA damage to the DDR and cell cycle checkpoint pathways. 
Initial damage is sensed by proteins including the histone -H2AX, which is rapidly phosphorylated by ATM at a specific serine 
residue in response to chromatin structure alteration at double stranded break sites, activating recruitment of repair proteins including 
BRCA1 and the MRN complex (MRE11, Rad51, NBS1). DSB repair is undertaken by the end-joining pathway involving the kinase 
DNA-PK and Ku protein binding partners and the homologous recombination pathway involving Rad51 and associated proteins. 
Single strand breaks (SSB) and replication stress leading to stalled replication forks activate PARP which in turn recruits repair factors 
including XRCC1 and promotes chromatin remodeling at the break site and base excision repair. ATR and ATM function both in the 
initial signaling cascade and as transducers to downstream activation of the cell cycle checkpoints inhibitors, Chk1 and Chk2 
producing cell cycle delay to facilitate repair. Points in the pathway at which specific inhibitors are available are indicated. As 
predicted from their roles in the DDR pathway, ATM and ATR inhibitors sensitize to a broad range of DNA damaging agents causing 
single or double strand breaks. PARPi and cell cycle checkpoint inhibitors including Wee1 inhibitors are specifically effective in cells 




















































































































































Figure 12; An expanded pharmacopoeia of metabolic drug targets in glioblastoma (Adapted with permission from Bi et al. 
Nature Rev Cancer 2020;20:57-70 . The extensive focus on altered glioma metabolism has led to a considerable expansion in the list 
of potential drug targets. Receptor tyrosine kinase (RTK)-driven metabolic dependencies have also been identified. For example, 
epidermal growth factor receptor (EGFR) amplification produces major changes in metabolic enzyme dependencies, including in 
glucose uptake, glycolysis, fatty acid (FA) synthesis, membrane lipid remodelling, cholesterol uptake, NAD+ production and 


































































































































phosphatidylcholines (PCs) and disrupts plasma membrane localization of EGFR variant III (EGFRvIII), which blocks EGFRvIII- 
driven oncogenic signalling and suppresses glioblastoma (GBM) tumour growth. LXR-623, a brain- penetrant liver X receptor (LXR) 
agonist, targets the cholesterol homeostasis of GBM cells by promoting ATP- binding cassette subfamily A member 1 (ABCA1)-
mediated cholesterol efflux and inhibiting low- density lipoprotein receptor (LDLR)-mediated cholesterol uptake. Isocitrate 
dehydrogenase (IDH) mutants in glioma cells generate the oncometabolite d-2-hydroxyglutarate (D2HG), which defines the 
dependencies of NAD+ and glutathione (GSH) production and impacts epigenetic events in glioma cells. The oxidative 
phosphorylation (OXPHOS) inhibitors, including metformin, Gboxin and IACS-010759, target glioma cells by inhibiting 
transmembrane protein complexes in the mitochondrial inner membrane, known as the electron transport chain (ETC). 2DG, 2-deoxy- 
d-glucose; 2PG, 2-phosphoglyceric acid; αKG, α- ketoglutarate; ACBP, acyl- CoA-binding protein; ACLY, ATP citrate lyase; 
ACSS2, acetyl- CoA synthetase; AMPK , AMP- activated protein kinase; BCAA , branched- chain amino acid; BCAT1, branched- 
chain amino acid transaminase 1; BCKA , branched- chain keto acid; BRD4, bromodomain containing 4; DCA , dichloroacetate; 
ELOVL2, ELOVL FA elongase 2; FASN, FA synthase; GDH1, glutamate dehydrogenase 1; GLS, glutaminase; GLUT1, glucose 
transporter 1; HSPD1, heat shock protein family D (Hsp60) member 1; IDH1, isocitrate dehydrogenase 1; LDHA , lactate 
dehydrogenase A ; MCT1, monocarboxylate transporter 1; NA , nicotinic acid; NAMPT, nicotinamide phosphoribosyl-transferase; 
NAPRT1, nicotinate phosphoribosyltransferase domain containing 1; NM, nicotinamide; PDK , pyruvate dehydrogenase kinase; PEP, 
2-phosphoenolpyruvate; PKM2, pyruvate kinase muscle isozyme M2; SHMT1, serine hydroxymethyltransferase 1; TCA , 


































































































































Figure 13: Challenges to effectively treat GBM include (top) the presence of the blood brain barrier that precludes the 
delivery of many drugs into the brain coupled to (middle) an immunosuppressive microenvironment and (bottom) 
compensatory signaling networks that can render GBM therapies ineffective.  
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